

Review

Melatonin Regulates Aging and Neurodegeneration through Energy Metabolism, Epigenetics, Autophagy and Circadian Rhythm Pathways

Anorut Jenwitheesuk¹, Chutikorn Nopparat¹, Sujira Mukda¹, Prapimpun Wongchitrat² and Piyarat Govitrapong^{1,3,*}

¹ Research Center for Neuroscience, Institute of Molecular Biosciences, Mahidol University, Salaya, Nakornpathom 73170, Thailand; E-Mails: anorutj@gmail.com (A.J.); chukorn.nop@mahidol.ac.th (C.N.); sujira.muk@mahidol.ac.th (S.M.)

² Center for Innovation Development and Technology Transfer, Faculty of Medical Technology, Mahidol University, Salaya, Nakornpathom 73170, Thailand; E-Mail: prapimpun.won@mahidol.ac.th

³ Center for Neuroscience and Department of Pharmacology, Faculty of Science, Mahidol University, Rama VI Road, Bangkok 10400, Thailand

* Author to whom correspondence should be addressed; E-Mail: piyarat.gov@mahidol.ac.th; Tel./Fax: +662-441-9003 (ext. 1311).

Received: 25 July 2014; in revised form: 3 September 2014 / Accepted: 12 September 2014 /

Published: 22 September 2014

Abstract: Brain aging is linked to certain types of neurodegenerative diseases and identifying new therapeutic targets has become critical. Melatonin, a pineal hormone, associates with molecules and signaling pathways that sense and influence energy metabolism, autophagy, and circadian rhythms, including insulin-like growth factor 1 (IGF-1), Forkhead box O (FoxOs), sirtuins and mammalian target of rapamycin (mTOR) signaling pathways. This review summarizes the current understanding of how melatonin, together with molecular, cellular and systemic energy metabolisms, regulates epigenetic processes in the neurons. This information will lead to a greater understanding of molecular epigenetic aging of the brain and anti-aging mechanisms to increase lifespan under healthy conditions.

Keywords: melatonin; brain aging; energy metabolism; epigenetics; autophagy; circadian rhythm; neurodegeneration; sirtuins

1. Introduction

Understanding the underlying mechanisms of age-dependent alterations in brain structure and functions has become critical for identifying new therapeutic targets and for developing multimodal health-care strategies that meet the needs of an aging population. The pathological processes in the aging brain are associated with molecules and signaling pathways that sense and influence energy metabolism, e.g., insulin, insulin-like growth factor 1 (IGF-1), Forkhead box O (FoxOs), sirtuins (SIRT), autophagy, circadian rhythms and mammalian target of rapamycin (mTOR) signaling pathways. Melatonin, a hormone primarily secreted by the pineal gland, is synthesized from tryptophan under the control of numerous enzymes that are inhibited or stimulated by the light/dark cycle [1,2]. Nocturnal melatonin is a signal to mediate the circadian message for the entire body. Pineal melatonin displays a circadian pattern driven by primary circadian clock signals from the suprachiasmatic nucleus (SCN).

Melatonin not only associates with the energy metabolism pathways but also regulates epigenetic processes in neuronal cells. Energy metabolism is a vital modulator of epigenetic processes of the neural system. Melatonin associates with molecules and signaling pathways that sense and influence energy metabolism, including insulin/IGF-1 [3,4], FoxO and sirtuin pathways [5–7]. These pathways are now implicated in the epigenetic processes of both young and aging brains and associated with neurodegenerative diseases. The effects of melatonin in regulating energy metabolism, modulating epigenetics in normal brain aging and neuropathological aging will be discussed. An understanding of how neuronal cells are influenced by energy availability will explain the complex nature of the aging brain in both normal and diseased states.

2. Brain Energy Metabolism

2.1. Insulin/IGF-1 (Insulin-Like Growth Factor 1) Signaling Pathways and Brain Energy

Neurons require energy to support action potentials, neuronal plasticity and neurotransmission; thus, age-related neuronal energy deficits contribute to the cognitive decline and to the pathogenesis of several neurodegenerative disorders [8]. Insulin/IGF-1 signaling pathways establish a complicated signaling network with close connections to mitochondrial bioenergetics, biogenesis and redox homeostasis [9,10]. Insulin and IGF-1 bind to their receptors on the cell surface, leading to the phosphorylation of tyrosine residues on the insulin receptor and the IR substrate. Then, IGF-1 further regulates many cascade pathways. For example, IGF-1 activates phosphoinositide 3 kinase-protein kinase B (PI3K–Akt) signaling and then inactivates FoxO transcription factors [11].

Although a decrease in the activation of the insulin/IGF-1 pathway seems to extend the longevity, normal brain functions require a normal insulin/IGF-1 signaling cascade [12,13]. This pathway regulates synaptic plasticity and neuronal survival via the maintenance of neuronal mitochondria during aging [10]. Ames dwarf mice showed a longer lifespan and normal cognitive function in advanced age. These mice showed very low growth hormone (GH) level and undetectable IGF-1 in circulation but increased hippocampal GH and IGF-1 protein levels as compared with the wild type. Increased phosphorylation by Akt and cyclic AMP responsive element-binding protein (CREB) were also detected in the hippocampus of Ames dwarf mice. These features might contribute to the maintenance of

cognitive function during aging [14,15]. In addition, over-activated insulin and PI3K/Akt pathways were associated with many pathology characteristics of Alzheimer's disease (AD) [16,17].

Accumulating evidence suggests that low levels of circulating IGF-1 and impairments of insulin/IGF-1 signaling in the brain contributed to age-dependent cognitive decline, such as Alzheimer's disease [18,19]. As seen in the Rotterdam Study, which surveyed 1014 persons for the prevalence of dementia, a higher level of IGF-1 receptor stimulating activity was associated with a higher prevalence of dementia [8,20]. In addition, the insulin resistance observed in diabetes constitutes a risk factor for Alzheimer's disease [21,22]. On the other hand, the insulin/IGF-1 system is involved in many protective pathways. For example, the PI3K/Akt pathway entails phosphorylating FoxO transcription factors, resulting in shuttling phosphorylated FoxO from the nucleus to the cytosol, thereby preventing the transcription of FoxO-driven pro-apoptotic genes [23,24]. Additionally, the anti-apoptotic effect of PI3K–Akt signaling is a consequence of the phosphorylation and inhibition of glycogen synthase kinase 3 β (GSK3 β), which, in its active form, phosphorylates anti-apoptotic Bcl-2 and Bcl-xL. Insulin prevents cytochrome c release in the perfused brain in a PI3K-dependent pathway. Insulin increases the total and surface expression of glutamate transporter in astrocytes by a pathway involving the PI3K–Akt/mTOR signaling cascade [25].

2.2. Melatonin and Metabolic Pathways

Melatonin (*N*-acetyl-5-methoxytryptamine) is a molecule that is secreted by the pineal gland and that can also be produced in the retina, extraorbital lacrimal gland, Harderian gland, gastrointestinal tract, blood platelets, and bone marrow cells [1,2,26]. Multiple actions of melatonin include: (i) G-protein-coupled melatonin receptors signaling cascade; (ii) inducing QR2; (iii) destroying reactive oxygen and reactive nitrogen species; (iv) increasing calmodulin degradation; (v) binding to nuclear receptors to alter the transcription of target genes; and (vi) modulating hemopoiesis and immune cell production and function [27–29].

Melatonin is involved in energy expenditure and body weight regulation. In pinealectomized rats, after an increase in body weight and exogenous melatonin supplement, reverse body weight gain occurs. Similar effects on reduced body weight and visceral fat were observed in both young and middle-aged rats. Additionally, this effect on decreased weight gain can be found in animals fed either a high-fat diet or high fructose [30,31]. The melatonin receptor seems to play a role in obesity. Selective agonists of melatonin receptor type 1 (MT1) and melatonin receptor type 2 (MT2), piromelatine (NEU-P11) and ramelteon, had similar effects on decreasing body weight and blood pressure, which were similar to melatonin-induced effects [32].

Pinealectomy caused a lack of melatonin in rats, which displayed reduced insulin sensitivity and reduced GLUT4 gene expression [33]. In humans, melatonin may improve metabolic syndrome via its anti-hyperlipidemic action. Melatonin inhibits insulin release through MT1 and MT2, which are expressed in pancreatic β -cells [34]. Altered plasma melatonin rhythms in weight-matched type 2 diabetes and non-diabetic individuals support a possible role of melatonin in type 2 diabetes etiology [35,36].

Melatonin is associated with the sensing processes for metabolic status by the primary pathways involved with the insulin/IGF-1 pathway [37]. The cellular energetic state is believed to respond

through the activation of different mechanisms, with the best-known mechanism involving NAD⁺-dependent deacetylases, which are called sirtuins [38,39]. This mechanism will be introduced and discussed in Section 2.4.

Insulin, growth hormone (GH) and IGF-1, integrate many physiological responses during aging. Reducing activation of the PI3-K/Akt signal can extend lifespan in organisms from yeast to mammals. In *Caenorhabditis elegans*, genes known to be involved in the insulin/IGF-I pathway include *dauer-constitutive-2* (*daf-2*), which is a homolog of insulin/IGF-1-like receptor, as well as *daf-16* (Forkhead transcription factor) and *daf-18* (PTEN, Phosphatase and tensin homolog). Mutations in these factors result in increased or decreased lifespan [40–43].

Mammalian models with reduced GH and/or IGF-1 signaling increase longevity compared with intact animals. Mutant mice with anterior pituitary dysfunctions, such as Snell (defect in the pituitary specific transcription factor-1 gene (*Pit-1*)) and Ames dwarf mice (recessive point mutation in the prophet of *Pit1* (*Prop-1*) or paired-like homeodomain transcription factor in *Prop-1*), show dwarf characteristics, female infertility and severely low insulin, IGF-1, glucose, and thyroid hormone level. Interestingly, these mice have a greater than 40% increase in lifespan. The prolonged lifespan effects were also found in mice with the defect in IGF-1 or in the IGF-1 receptor and in *lit/lit* mice, which have a mutated GH-releasing hormone receptor. On the other hand, GH transgenic mice have early puberty, elevated IGF-1 and insulin levels and develop insulin resistance. The lifespan of these mice is significantly shorter compared with the wild-type animals [44–46].

Melatonin has been implicated in obesity and in the regulation of insulin activities. Studies in pinealectomized animals induced insulin resistance and glucose intolerance in type 2 diabetic rats [3,47]. Melatonin influences MT1- and MT2-receptor-mediated insulin secretion both *in vivo* and *in vitro*. Melatonin displays a protective effect against reactive oxygen species (ROS) generation in pancreatic β -cells, which are easily susceptible to oxidative stress. The plasma melatonin level and arylalkylamine-*N*-acetyltransferase activity are lower in diabetic rats than in nondiabetic rats. In contrast, arylalkylamine-*N*-acetyltransferase mRNA increased, and the insulin receptor mRNA decreased in the pineal gland, which indicated a close relation between insulin and melatonin [34,41,48]. Melatonin is associated with chronic inflammation in obesity. Obese animals have higher serum levels of interleukin-17 (IL-17). Insulin and IGF-1 increase IL-17-induced expression of inflammatory chemokines/cytokines via a GSK3 β dependent pathway, which is inhibited by melatonin via suppression of Akt activation [49].

Melatonin injections resulted in increased circulating GH levels and increased serum IGF-I levels, concomitantly lowering somatostatin levels. These results are associated with significantly decreased hypothalamic norepinephrine turnover [4,50]. The GH rhythm was suppressed in pinealectomized rats; after melatonin replacement in these rats, GH and IGF-1 levels increased during the day [3].

The effects of melatonin on PI3k/Akt signaling in peripheral tissues compared with the brain are different and depend on the stress or injury model. For instance, melatonin showed the protective effects against brain injury by activating Akt and its downstream targets in a middle cerebral artery occlusion model [51] and a kainic acid-induced hippocampal excitotoxicity model [52]. In aged neuronal cell culture, melatonin increased Akt activation, subsequently leading to GSK3 β inhibition and an increase in FoxO1 phosphorylation [53]. The effects of melatonin and PI3K–Akt activities in the brain still need to be further explored.

2.3. Epigenetics and Aging

Epigenetic processes regulate gene expression caused by modifications at the chromatin level without modifying the DNA sequence. These novel studies represent a bridge between environments, aging and individual genetic backgrounds. Epigenetic are currently considered part of age-related neuropathological phenotypes [54–56].

DNA methylation is the process that silences DNA sequences. During aging, 5-methyl-cytosine distribution is found changing across the genome and leading to decreased global DNA methylation. However, some promoters become hypermethylated [56]. DNA methylation and DNA hydroxymethylation, which is the oxidized form of DNA methylation, are also the centers of interest in epigenetic studies of Alzheimer's disease. Global levels of DNA methylation and DNA hydroxymethylation positively correlate with markers of Alzheimer's disease, including amyloid beta (A β), tau, and ubiquitin expression [57].

Histone acetyltransferase (HAT) and histone deacetylases (HDACs) are the posttranslational modifiers of histones. Histone acetylation is catalyzed by HATs, whereas deacetylation is catalyzed by HDACs. Several different families of HATs and HDACs have been identified. Eighteen HDAC enzymes have been identified in humans and have been categorized into 4 classes, including class I, II, III, and IV. Class I, II, and IV members are zinc-dependent enzymes, whereas the class III family includes nicotinamide adenine dinucleotide (NAD⁺)-dependent enzymes. The sirtuins family belongs to this class.

Aging disrupts the epigenetic processes involved with synaptic plasticity and memory in the hippocampus [58]. Epigenetic features during aging, such as lower HDACs activity in the hippocampus [59], are concomitant with higher chromatin repression, such as di-methyl and tri-methyl histone H3K9 in aging brain [60]. In addition, the senescence mouse model studies have demonstrated epigenetic variation in an age-dependent manner. In senescence-prone mice, learning and memory deficits are associated with losses of monomethyl histone H4K20 and tri-methyl H3K36, which are known to facilitate transcription in the hippocampus. When senescence-accelerated mouse prone 8 (SAMP8) mice are compared with age-matched senescence-accelerated-resistant mouse (SAMR1) mice, many methylated histone modifications changed were found in SAMP8 such as methylated H4K20, H3K27, H3K36 and di-methylated H3K79 [61]. Global histone H3 acetylation levels were reduced in SAMP8 mice compared with control SAMR1 mice [62].

The links between histone acetylation dynamics and hippocampus-dependent memory are emphasized by the effects of histone deacetylase inhibitor administration. Direct infusion of triclosan A into the CA1 layer of hippocampus can interrupt the memory system in young mice but not in aged mice [63]. EVX001688, which is a long-lasting histone acetylation enhancer, increased histone acetylation levels during training in a contextual fear conditioning task in young rats but showed no effect on performance in aging [64].

CREB-binding protein (CBP) and p300 have HAT activity. The CBP/p300 complex has the highest level in the brain and relatively high levels in the lung, spleen, and heart. CBP and p300 are relatively stable in the hippocampus with advancing age [65]. However, this complex may play an important role in developing processes because p300 and CBP are highly expressed in the brains and livers of fetal and newborn mice [66]. CBP and p300 are involved in memory consolidation processes. While spatial

memory is being consolidated in the rat dorsal hippocampus, an increase in HAT activity, together with global increases in CBP, p300, and PCAF expression, can enhance the memory task [67].

Insulin and IGF-1 are associated with epigenetic variations in the brain. Valproic acid, which is a histone deacetylase inhibitor, induces weight gain and increases the risk of insulin resistance. This drug regulated the expression of adipokine genes in hypothalamic neurons via modulating the activity of the CCAAT enhancer-binding protein alpha (CEBP α) [68].

Age-dependent metabolic syndrome is a risk factor for impaired cognition and for Alzheimer's disease. Altered DNA methylation and insulin resistance in the brain are associated with pathogenesis from soluble A β in Alzheimer's disease [69]. IGF-1 provides neuroprotective effects via action against HDAC1 and HDAC3. HDAC1 expression is upregulated in the brains of the Huntington disease model and the Ca²⁺/calmodulin-dependent protein kinase (CaMK)/p25 double-transgenic model of tauopathic degeneration. The effect of HDAC1 can be inhibited by IGF-1 expression, Akt expression, or GSK3 β inhibition [70]. The epigenetic mechanisms due to cellular energy pathway should be further studied in order to elucidate age-related neuropathogenesis.

2.4. Sirtuins

The yeast silent information regulator gene and its mammalian homologs, sirtuins, are the centers of interests in aging research. Seven sirtuins (SIRT1–SIRT7) are found in mammals. Sirtuin1 (SIRT1) regulates epigenetic, DNA repair, aging, and programmed cell death and defends against neurodegenerative diseases. The longevity effects of SIRT1 are expected to rely on its enzymatic deacetylation activity on histone and non-histone substrates (more details in a later section).

Sirtuin is the HDAC that requires NAD as the regulator and co-factor for enzymatic activity. NAD is one of the electron transport chain factors and plays an important role in regulating cellular energy. Nicotinamide phosphoribosyltransferase (NAMPT) and nicotinamide/nicotinic acid mononucleotide adenylyltransferase (NMNAT) are the key enzymes for NAD biosynthesis. NAMPT is the rate-limiting enzyme in NAD biosynthesis, whereas NMNAT completes NAD biosynthesis by transferring adenine from ATP to NMN [71]. SIRT1 and the NAD pathway play a role in linking cellular energy with aging. Intracellular NAD⁺ levels and the NAD:NADH ratio in the heart, lung, liver and kidney of female Wistar rats decline in middle-aged rats (12 months old) compared with young (3 months old) rats. Decreases in SIRT1 activity and increased acetylated p53 levels were observed in a variety of organ tissues in parallel with a decrease in NAD⁺ levels [72]. A connection was found between NAD biosynthesis and sirtuins associated with the aging process. Depleting cellular NAD⁺ stores attenuates SIRT1 deacetylase activity, leading to many effects, such as SIRT1 regulation of p53 and some apoptotic factors. This change resulted in increased cell death via apoptotic mechanisms [72,73]. SIRT1-mediated deacetylation can bind several transcription factors and cofactors, including FoxO transcription factors, p300/CBP-associated factor and peroxisome proliferator-activated receptor gamma (PPAR- γ) [71].

SIRT1 is expressed in the brain, with high expression levels in the cortex, hippocampus, cerebellum and hypothalamus but low expression in white matter [74]. SIRT1 is abundantly expressed in several areas, particularly in arcuate, paraventricular, ventro- and dorsomedial hypothalamic nuclei [75,76]. These hypothalamic areas regulate food intake and energy expenditure that link SIRT1 to metabolic

status. SIRT1 protein in hypothalamus was high after feeding and low during fasted condition [75,77]. In addition, SIRT1 is associated with hormones and neuropeptides that regulate food intake such as leptin [78] and neuropeptide Y/Agouti-related peptide [79]. Further study of SIRT1 in the hypothalamic system will lead to a greater understanding of how caloric restriction (CR) extends lifespan and neuroprotection during aging.

2.5. Forkhead Box O (FoxO)

This sirtuin1 targets that are closely linked with insulin/IGF-1 and with energy homeostasis are Forkhead box O (FoxO) transcription factors. The FoxO family has four members, namely, FoxO1, FoxO3, FoxO4, and FoxO6 [11]. FoxOs are regulated by the insulin signaling pathway and have been implicated in regulating metabolism, cellular proliferation, tumorigenesis, the stress response [80], apoptosis [23], neurogenesis [81] and benefit effects of caloric restriction [46,82]. FoxO1 activation in peripheral tissue interferes with gluconeogenesis and with carbohydrate/lipid pathways [83]. Insulin-PI3K-FoxO3 signaling is required for circadian rhythm (for details, see Section 4) in the liver via regulation of *Clock* in PI3K- and FoxO3-dependent manners [84]. In the brain, SIRT1 and FoxO1 controls food intake through transcriptional regulation of the orexigenic neuropeptide Y, agouti-related protein [75,77].

FoxOs link insulin/IGF-1, SIRT1 and hippocampal functions [85]. FoxO6 is highly enriched in the adult hippocampus and is required for memory consolidation. FoxO6-deficient mice display normal learning but impaired memory consolidation in contextual fear conditioning and in novel object recognition [86]. FoxO is fundamental in the pathogenesis of neurodegeneration, such as in FoxO effects on the oxidative stress response upon manganese-induced Parkinson's disease [87]. FoxO3 contributes to apoptosis, to β -amyloid-induced neuron death [88], and to the accumulation of α -synuclein, which controls the fate of dopaminergic neurons in the substantia nigra [89].

2.6. Melatonin and Epigenetics

Epigenetic actions of melatonin that relates to brain aging and neurodegenerative diseases remain poorly characterized. Since both cellular senescence and cancer cell development involve epigenetic alterations, understanding the epigenetic mechanisms of anti-cancer properties of melatonin may provide the explanation for brain aging-related conditions.

Melatonin causes epigenetic effects against cancer cells by modulating both DNA methylation and histone acetylation pathways. Melatonin has been expected to epigenetically affect DNA methylation in breast cancer; however, the mechanism is unclear [90,91]. Melatonin-treated MCF-7 cells show an inverse correlation with DNA methylation levels and with alterations in oncogenic genes *EGR3* and *POU4F2/Brn-3b*, whereas the tumor suppressor gene *GPC3* was upregulated by melatonin [92]. The hypermethylation of the CpG island in the promoter region of the MT1 receptor inversely correlated with its expression in oral squamous cell carcinoma [93].

Recent reports have indicated that melatonin has an effect on histone modification. Melatonin can restore liver histone deacetylase, DNA methyltransferase activity, and DNA methylation [94]. Prenatal dexamethasone exposure unregulated HDAC1 expression in the kidneys of offspring. Maternal melatonin co-therapy with dexamethasone attenuated prenatal-induced hypertension by restoring

nephron numbers and by modulating HDAC-1, HDAC-2, and HDAC-8 [95]. When neural stem cells are treated with melatonin, significantly increased histone H3 acetylation and enhanced HDAC isoforms were observed as compensatory mechanisms after melatonin-induced histone hyperacetylation. This epigenetic effect of melatonin acts via the MT1 receptor [96,97].

p300 is abundantly expressed in cancer cells, and p300 over expression enhances cyclooxygenase-2 (COX-2) activation induced by diverse proinflammatory mediators. Melatonin significantly suppressed the proliferation of human MDA-MB-361 breast cancer cells and induced apoptosis in a dose-dependent manner. This melatonin-suppressed proliferation was accompanied with inhibited COX-2, p300, and nuclear factor kappa-light-chain-enhancer of activated B cells (NF- κ B) signaling. Melatonin inhibits p300 HAT activity and p300-mediated NF- κ B acetylation, thereby blocking NF- κ B binding and p300 recruitment to the COX-2 promoter [98]. Melatonin also suppresses p300 histone acetyltransferase activity and p300-mediated NF- κ B acetylation in the human vascular smooth muscle cell line CRL1999 [99]. The epigenetic effect of melatonin may correlate with nuclear factor erythroid 2-related factor 2 (Nrf2). Melatonin exhibits an anti-inflammatory effect by suppressing pNF- κ B but promoting Nrf2 expression [100–102]. The CBP/p300 complex directly acetylates Nrf2 in response to arsenite-induced stress. This acetylation leads to increased promoter-specific DNA binding of Nrf2 and establishes acetylation as a novel regulatory mechanism that modulates the Nrf2-dependent antioxidant response. Nrf2-dependent antioxidant enzyme expression is also dependent on Nrf2 acetylation by CBP/p300 machinery [103,104].

2.7. Melatonin and Sirtuin System

SIRT1 has been shown to link with aging and cancer. During aging, SIRT1 expression and its activity declined while it is highly expressed in several types of cancer cells. Melatonin protected aging neurons via preserving the relative protein levels of sirtuin1 in SAMP8 mice [5–7] and in hippocampus of total sleep-deprived rats [105] but decreased overexpressed sirtuin1 in cancer such as prostate cancer [106,107] and human osteosarcoma [108]. The supportive effect of melatonin on sirtuin1 may act via the NAD system. Melatonin acts as an effective antioxidant to preserve NAD levels under oxidative stress [109]. Melatonin also indirectly regulates SIRT1 expression involved with SIRT1 targets, e.g., p53 [5,6]. Melatonin prevents the activation of ataxia telangiectasia mutated, which is an enzyme involved in p53-related apoptotic pathway activation. Moreover, melatonin treatment of neuronal cell cultures also decreases E2F-1, which is a proapoptotic transcription factor [53].

Melatonin may modulate energy homeostasis through the SIRT1-FoxO pathway. The other interesting SIRT1 target is FoxOs. Melatonin may promote FoxOs activities through upregulating SIRT1 and SIRT1 deacetylate FoxOs, leading to transport of this transcription factor to the nucleus. Additionally, melatonin inhibits CREB-binding protein (CBP) and p300 in breast cancer cells in which p300 is expressed at a high level. The cancer cell proliferation was accompanied by significant inhibition of p300 histone acetyltransferase activity and p300-mediated NF- κ B acetylation by melatonin, thereby blocking NF- κ B binding and p300 recruitment to the COX-2 promoter [98]. The acetylation of FoxOs via CBP and p300 decreases DNA binding and also decrease activities of FoxOs. CBP is a protein that binds to cyclic adenosine monophosphate-regulated enhancer-binding protein, and homologue protein, p300. This complex has the histone acetyltransferase activity [67].

These target genes may act as the feedback regulator in the SIRT1-FoxOs pathway. Since, FoxOs are regulated by the insulin signaling and play important roles in cellular stress response, further studies will clarify the neuroprotective effects of melatonin during the imbalance of energy homeostasis.

3. Autophagy

3.1. Autophagy and the Aging Process

Autophagy is characterized by the sequestration processes of cytoplasmic material within an autophagosome for degradation by lysosomes. Autophagy acts as a pro-survival mechanism for maintaining normal cellular functions and serves as an adaptive response during various stress conditions, such as amino acid starvation, an unfolded protein response or viral infection. Since the brain requires a lot of energy for action potential generation and other processes, the age-related decline in metabolism contributes to cognitive decline and is a risk factor for neurodegenerative disorders. These diseases may occur when neurons fail to adapt to decreases in basal energy availability [110,111] that correlate with controlling cell homeostasis by the autophagy process. Autophagy is negatively regulated by the mammalian target of rapamycin (mTOR) signaling pathway and by a downstream cascade of autophagy-related proteins (Atg), such as Atg1, Beclin 1 (Atg6), LC3 (Atg8) and Atg5 [112].

The mTOR pathway is another major signaling pathway that affects aging. Activation of this pathway is nutrient-dependent and responds by an energy shift during cellular growth and division. mTOR is a member of the PI3K-related kinase family, which regulates cell growth and proliferation by modulating protein synthesis and transcription. The mTOR complex 1 (mTORC1) consists of mTOR, regulatory associated protein of mTOR (Raptor), LST8/G-protein β -subunit-like protein (mLST8/GbL) and PRAS40. mTORC1 is stimulated by growth promoting conditions but is inhibited by a low nutrient status, growth factor deprivation, stress and the specific inhibitor rapamycin. The TSC1-TSC2 (tuberous sclerosis complex1/2) inhibitory complex is upstream of the mTORC1 pathway. This complex functions as a GTPase activating protein (GAP) for the GTPase Rheb, which is an mTOR activator. The TSC1-TSC2 complex inactivates Rheb to inhibit mTOR signaling. A variety of growth and stress signals regulate mTORC1 signaling through the TSC1-TSC2 complex [113,114]. TORC1 is activated by amino acids, and insulin/IGF-1 is activated through AKT. Activated AKT phosphorylates and inhibits the TSC1-TSC2 complex. The TSC1-TSC complex can also be regulated by AMP-activated kinase (AMPK) and by Ras homolog enriched in brain (RHEB), which binds to and activates TORC1 in a GTP-dependent manner [115,116].

mTORC1 signaling has been shown to influence aging in many organisms. Reduced TOR activity enhances longevity in lower organisms, such as yeast, worms and flies, through higher mammalian animals, such as rodents. mTOR has been strongly linked to the ribosomal protein S6 kinase (S6K), which is a downstream target of TOR. S6K inhibition reduces protein synthesis and extends lifespan in many animal models [117].

Macroautophagy is also a factor that is repressed during aging [118]. When *Atg6*, *Atg7*, and *Atg12*, which are regulators of macroautophagy, are knocked down, the lifespan is reduced in a *C. elegans*

model [119,120]. Furthermore, the knockout of *bec-1*, which is an ortholog of the autophagy gene *beclin-1*, suppressed the lifespan in *C. elegans* [119].

The age-related decline in autophagy function may be associated with many age-associated diseases, including neurodegeneration, in normal diet-fed animals and the onset of the disease slowed by caloric restriction treatment [121,122]. Autophagic activity decreases during the course of aging and genes that control brain aging process are strongly associated with lifespan regulation in flies and worms [123]. Autophagy deficiency leads to abnormal accumulation of protein aggregates thus promoting pathological mechanisms associated with neurodegenerative disorders, such as Huntington and Alzheimer's disease [124,125]. Moreover, the age-induced memory impairment suggests that cognitive function in aging is strongly associated with the autophagic pathway [126]. Many studies support that primary defects in macroautophagy contribute to the pathogenesis of AD. Most studies focus on the relevance of autophagic dysfunction in AD pathogenesis [127] by the intraneuronal aggregates of protein tau, forming neurofibrillary tangles and extra-neuronal β -amyloid senile plaques [128]. In mouse models of AD, reduced IGF-1 signaling protects from disease-associated neuronal loss and behavioral impairment [129]. In addition, lower levels of the autophagy gene *beclin1* have been observed in human aging brains [125].

Several studies have elucidated that CR-linked lifespan extension is dependent on autophagic degradation in *C. elegans* via autophagosome formation. Autophagy genes play a role in reducing mitochondrial respiration or in reducing TOR activity and increasing longevity in mutant nematodes [130]. Unfortunately, the protein modification processes essential to controlling the autophagic process remain unclear. The role of other signaling pathways and target protein modifications, such as acetylation, must also be further studied.

3.2. Autophagy and Sirtuin Pathways

Neurodegeneration such as Alzheimer's disease is closely linked to the metabolic status and numerous reports have demonstrated that SIRT1 and autophagy are correlated with the balance between NAD^+ /NADH for maintaining metabolic homeostasis and cellular survival. SIRT1 may yield the protective effects against AD through modulating autophagy processes. SIRT1 expression could be inhibited by 3-methyladenine (3-MA), which is an autophagy inhibitor. SIRT1 also regulates cellular metabolism through nutrient-sensing pathways, such as AMPK and TOR pathways [131].

AMPK inhibits mTOR and evokes autophagocytosis by resveratrol. Resveratrol binds to phosphodiesterases and triggers cAMP signaling to activate SIRT1. Resveratrol induces autophagy in a SIRT1-dependent manner [132]. An increase in the energetic AMP/ATP ratio activates AMPK, increases NAD^+ levels and stimulates SIRT [133]. SIRT1 overexpression stimulates the level of autophagy [134]. High calorie diet-fed mice exhibit shorter lifespan, and resveratrol normalizes this effect, suggesting that the AMPK/SIRT1 pathway is involved [135].

The acetylation process plays a significant role in autophagy regulation. The clearance of mutant *huntingtin* through autophagic degradation can be regulated by acetylation at its Lys444 residue [136]. During growth factor deprivation, GSK3 activates acetyltransferase TIP60 through phosphorylating TIP60-Ser86. Activated TIP60 directly acetylates, thereby stimulating the protein kinase ULK1, which is required for autophagy induction [137,138]. Thus, the acetylation of autophagy-related proteins

plays an important role in regulating autophagic flux. p300 can acetylate Atg5, Atg7, Atg8 and Atg12 proteins; acetylation by p300 also inhibits autophagy, whereas silencing p300 increases autophagic flux [139]. Atg8 deacetylation is regulated by SIRT1 [140]. Moreover, aggregating misfolded proteins may have an influence on autophagic function. This concept may explain secondary pathological mechanisms in many neurodegenerative diseases. SIRT1 overexpression is also reported to prevent microglia-dependent A β toxicity in Alzheimer's diseases through inhibiting NF- κ B signaling by deacetylating the lysine 310 residue of the RelA/p65 subunit of NF- κ B, thereby preventing its transcriptional activity [141]. In Parkinsonian models, resveratrol has a protective effect against rotenone-induced apoptosis and enhances α -synuclein degradation. These advantageous properties were shown to occur via autophagy induction [132]. Prolonged treatment with Longevinex, which is a resveratrol derivative, increased autophagy, and this increase correlated with an increase in SIRT1 levels and with FoxO nuclear translocation [142]. This observation suggests that SIRT1-mediated deacetylation of Atg proteins not only stimulates the autophagic uptake of cellular proteins during starvation but also promotes the degradation of damaged organelles to preserve homeostasis.

SIRT1 could promote the expression of components of the autophagy machinery via deacetylation of many transcription factors, which, in turn, activate autophagy genes. The FoxO family members are crucial to this process [143,144]. Under low nutrient conditions, FoxO transcription factors translocate to the nucleus, where these factors activate the expression of genes that are involved in energy metabolism and oxidative stress resistance, as well as of genes implicated in DNA damage repair, cell cycle arrest, apoptosis and autophagy [145–147].

FoxO1 activation results in the upregulation of Rab7, which is a small GTPase that mediates autophagosome-lysosome fusion. *Rab7* overexpression stimulates autophagy, whereas *Pab7* silencing inhibits FoxO1-induced autophagy. GTPase is required for mediating FoxO1-induced autophagic flux. In addition, deacetylating FoxO3 by SIRT1 leads to the upregulation of pro-autophagic Bnip3. FoxO3 can increase the expression of multiple autophagy-related genes, such as *ULK2*, *beclin1*, *VPS34*, *Bnip3* and *Bnip3L*, *Atg12*, *Atg4B*, *LC3*, and *GABARAPL1* [145,148,149].

Genotoxic stress can induce autophagy in a p53-dependent process, and p53 can regulate autophagy-inducing genes [150]. A loss of function mutation in the p53 ortholog *cep-1* exhibits a longer lifespan in *C. elegans* by inducing autophagy [151]. However, p53 deficiency does not enhance the lifespan extension conferred by *sir2.1* overexpression. During oxidative stress, SIRT1 blocks the nuclear translocation of p53; therefore, SIRT1 can inhibit the nuclear function of p53, which acts as a transcriptional regulator [152].

3.3. Autophagy and Caloric Restriction (CR)

Restricting the calories in diet has been used as a method for increasing both the longevity and quality of life. Caloric restriction (CR) has been found to extend longevity and impacts on age related diseases in yeast, worms, insects and rodents; thus, this regimen has become the center of aging research interest [153,154]. In addition, reduced calorie intake improves memory and cognitive brain functions in aged animals [155–157] and decreases risk factors for neurodegenerative diseases [158,159], while high calorie diets increase the risk of neurodegenerative disease [135,160,161]. The longevity and health effects of CR appear to act through many pathways. The possible target pathways, including

TOR, AMPK, and sirtuins, can detect changes in specific metabolites, such as amino acids, ATP, and NAD⁺. Further evidence indicated that defective insulin receptor (*daf2* mutant) worms lived longer than control worms [42,46]. Moreover, knockdown of autophagy gene products, including *Atg7* and *Atg12*, was shown to shorten the lifespan of both wild type and *daf2* mutant *C. elegans* [162].

The Ser/Thr protein kinase TOR plays a key role in signaling nutrient limitation in the autophagy pathway [163]. In cells lacking sirtuins, CR can extend lifespan via TOR inhibition [164]. The absence of SIRT1 resulted in mTOR, S6K1, 4EBP1 and S6 phosphorylation. These data indicate a role for SIRT1 in mTORC1 regulation because the mTOR pathway is responsive to nutrient and cellular stress and is downregulated in response to stress signals. Therefore, CR appears to induce both SIRT1 and autophagy. During nutrient starvation, high mTOR activity leads to the phosphorylation of Ulk1 at Ser 757, interfering with the interaction between Ulk1 and AMPK to form a complex with Atg1 for autophagosome assembly [165]. Both SIRT1 activation by resveratrol and CR prolonged the lifespan of *C. elegans* only when these organisms are autophagy competent, and their effects are abolished by silencing *beclin1*. Both *beclin1* knockdown and SIRT1 knockout prevent autophagy induction and reverse resveratrol effects. Therefore, CR and resveratrol require functional SIRT1 to stimulate autophagy and to enhance longevity [166]. Interestingly, silencing SIRT1 eliminated autophagy stimulation by resveratrol and by nutrient deprivation in human cancer cell lines. These data show the same result as seen in CR treatment in *C. elegans*. Mouse embryonic fibroblasts derived from fetuses with homozygous SIRT1 deletions could not activate autophagy during starvation [134].

3.4. Autophagy and Neuroinflammation

The NF- κ B signaling pathway that plays a vital role to defense against cell damage and autophagy is regulated by the NF- κ B system. Autophagy can stimulate NF- κ B-dependent inflammatory responses [167], whereas an increase in autophagy can prevent inflammatory responses [168,169]. However, the role of NF- κ B signaling in autophagic degradation is unknown.

NF- κ B signaling can repress TNF α -induced autophagy. This suppression was linked to NF- κ B activation of mTOR kinase, which is an inhibitor of autophagocytosis [170]. The NF- κ B signaling pathway inhibits autophagy in macrophages by downregulating *Atg5* and *beclin1* expression, leading to the promotion of apoptosis and inflammation processes [171]. The formation of this condition is stimulated by NF- κ B signaling activation [172,173].

The NF- κ B pathway involves the I-kappaB kinase (IKK) complex, which contains IKK α and IKK β kinases. The mTOR/Raptor complexes in response to TNF α and insulin, are involved with IKK α and IKK β . The activation of the mTOR/Raptor complex by IKK α was induced by Akt kinase, whereas IKK β repressed the tuberous sclerosis complex (TSC), which is an mTOR/Raptor suppressor, thereby activating the mTOR kinase [174]. TNF α -activated IKK β suppressed TSC1 and triggered the mTOR pathway [175,176]. The NF- κ B-activating kinases IKK β and NF- κ B-inducing kinase can be selectively degraded by autophagy. Additionally, NF- κ B signaling can promote cell survival during the heat shock recovery period via autophagy. To support this notion, the inhibition of NF- κ B activation could block the autophagic response and increased cell death after exposure to heat shock stress [177]. HSP90 inhibition with geldanamycin interferes with this interaction and induces the degradation of these proteins by autophagy. Overexpressing SIRT1 protected mice from many types of pathogenic

inflammation, such as liver cancer [178]. SIRT1 and SIRT6 repressed a critical driver of inflammation NF- κ B, either by deacetylating p65 by SIRT1 or by SIRT6 interacting with histones at NF- κ B target genes [179,180]. HIF-1 α , which is the SIRT target protein, is involved in a proinflammatory response, and p65, which is related to this transcription factor, can be deacetylated and repressed by SIRT1 and by SIRT2 [181,182]. Histones at NF- κ B-regulated genes can also be deacetylated by SIRT6, leading to the repression of gene expression [183].

3.5. Melatonin and Autophagy

Melatonin can act as either pro- or anti-autophagy. It depends on the stage of autophagy. In normal physiological condition, autophagy acts as pro-survival to maintain homeostasis of the cells. In this situation, melatonin will help or activate autophagy for cell survival. On the other hand, when cells are exposed to ROS or toxic agents, autophagy (excessive levels) will shift to autophagic cell death. In this state, melatonin exhibits protective effects to inhibit excessive levels of autophagy. Several lines of evidence have suggested that melatonin protects against neuronal cell death from methamphetamine (METH) toxicity [184,185]. In addition, melatonin can protect cells from METH toxicity-induced autophagy overactivation leading to lower autophagic cell death [186]. Some lines of evidence have demonstrated that the interaction between beclin1 and anti-apoptotic Bcl-2 negatively regulates autophagy by blocking an essential protein in the autophagy signaling pathway [187,188]. Under normal conditions, Beclin1 binds to Bcl-2 to form the Bcl-2/Beclin 1 complex; however, this complex dissociates, causing increase autophagy levels, such as when Bcl-2 was activated by an upstream pathway, such as Bcl-2 phosphorylation by c-Jun N-terminal kinase 1 activation [189,190]. A novel role of melatonin in protecting against cell death from METH-induced autophagy is to dissociate the Bcl-2/Beclin 1 complex and its upstream cascades that lead to cell death [191]. However, melatonin also correlated with chaperone-mediated autophagy (CMA) signaling to increase protein degradation by inhibiting abnormal forms of their proteins. Melatonin and autophagy work synergistically to promote cell survival by decreasing oxidative stress and by delaying immunosenescence. Some experiments have been designed to study the role of melatonin during immunosuppression. Cyclosporine treatment exhibited increased autophagy during oxidative stress but not during aging, whereas autophagy was suppressed, and LC3-II expression was inhibited by melatonin treatment [192,193]. Melatonin can either induce or inhibit autophagy, depending on cellular requirements and oxidative stress levels. Likewise, the dual functions of autophagy (inducing cell survival or cell death) also require further studies to clarify the regulatory roles of melatonin in the complicated autophagy processes.

4. The Circadian System

The circadian clock is an endogenous system that acts as an internal time-keeping device, generating approximately 24 h variation in physiology and behavior. This daily variation is defined as circadian rhythms (circa = about; dies = day) [194]. The hypothalamic suprachiasmatic nucleus (SCN) is the master clock in mammals. Photic information from light is conveyed from the retina via the retinohypothalamic tract and is sent to the SCN. Then, the SCN produces synchronizing signals to control the phases of peripheral clock oscillation [195]. The mechanical clock gene system is formed

by a complicated transcription-translation feedback loop. The transcription factor CLOCK (circadian locomotor output cycles kaput) dimerizes with BMAL1 (brain and muscle ARNT-like 1) [196], forming the heterodimer CLOCK:BMAL1, which activates transcription by binding to the E-box (5'-CACGTG-3') and E-box-like promoter sequences [195]. The other CLOCK homologs, such as neuronal PAS (PER, ARNT, SIM) domain protein 2 (NPAS2), dimerize BMAL1, activating transcription and maintaining normal circadian rhythmicity [197,198]. The *Period* (*Per1*, *Per2*, and *Per3*) and *Cryptochrome* (*Cry1* and *Cry2*) genes are the targets of CLOCK:BMAL1 and control this transcription complex. The oligomerization and nuclear translocation of the PER:CRY complex results in the inhibition of CLOCK:BMAL1-mediated transcription [195,199]. Most of the clock genes exhibit 24 h fluctuation changes in the SCN and in peripheral tissues, except for *Clock*. *Clock* does not oscillate in the SCN [200]. Reverse erythroblastosis virus α (Rev-Erba) is a negative regulator of BMAL1 expression [201], whereas retinoic acid receptor-related orphan receptors α (ROR α) and ROR γ positively regulate BMAL1 expression [202] via ROR response elements (RORE) [203]. Further regulatory mechanisms include post-translational modification processes, such as acetylation, methylation, phosphorylation and sumoylation. These processes provide additional levels of regulation to sustain and stabilize the accuracy of the circadian oscillation based on the 24-h solar cycle [204].

4.1. Melatonin and the Regulation of Clock Genes

Melatonin is primarily secreted at night and is defined as the “hormone of darkness” [2,205,206]. The duration of the nocturnal peak of melatonin secretion also reflects the length of the night [207]. Therefore, the robust rhythms of melatonin are suspected to be a crucial factors for normal circadian function and good health [208].

The expression of melatonin receptors explains the direct action of melatonin in many organs. The presence of melatonin receptors in the SCN and circadian melatonin production represent the association between melatonin production and the circadian rhythm machinery. The light-dark cycle of clock gene expression has been investigated in both melatonin-proficient mice (C3H) and melatonin-deficient mice (C57BL). PER1 (Period 1), CRY2 (Cryptochrome 2), and BMAL1 displayed lower levels in the adrenal cortex of C57BL mice than in C3H mice [209]. In the mouse striatum, pinealectomized mice did not display circadian rhythms of *Per1* mRNA and PER1 protein levels [210]. Primary neuronal cultures derived from the murine striatum demonstrated that melatonin decreased *Per1* and *Clock* expression but increased *NPAS2* expression and showed no effect on the *Bmal1* level. However, these effects were not observed in MT1 knockout animals [211]. A melatonin experiment in hypertensive TGR (mRen2)²⁷ rats yielded a phase-dependent effect on *Per2* and *Bmal1* expression in the heart, particularly during the dark phase, suggesting that melatonin is involved in the clock gene regulatory system; however, the exact mechanisms have not been elucidated [212].

4.2. Epigenetic Regulation of Clock Genes

Histone phosphorylation, acetylation, and DNA methylation, which modify circadian *clock* gene expression, have been shown to follow circadian rhythms [213–216]. DNA methylation in the SCN participates in regulating circadian rhythms. A shorter 22 h life cycle in mice altered global transcription in the SCN and the genome-wide methylation profile, leading to global alterations in

promoter DNA methylation. These alterations included areas that contained clock genes and genes involved in synaptogenesis, axon guidance and hormone signaling. Behavioral, transcriptional and DNA methylation changes were reversible after re-entrainment to a 24 h per day cycle. Directly infusing a methyltransferase inhibitor to the SCN can suppress period changes. These data indicated that animals exposed to a 22 h light–dark cycle had long-lasting changes in the SCN transcriptome caused by altered DNA methylation processes [217–219]. Histone methyltransferase, MLL1, which methylates histone H3 at lysine 4 (H3-K4), is also associated with CLOCK and is recruited to promoters of CCGs in a circadian manner. H3-K4 methylation at these promoters also displayed rhythmicity and was linked to transcriptional activation [219]. Some reports have demonstrated that rapid phosphorylation of Histone 3 on Serine 10 (H3S10) in the SCN is triggered in response to light. This phosphorylation results in the induction of *Per1* and immediate-early gene expression, such as *c-fos*, indicating that light-mediated signaling regulates circadian gene expression by remodeling chromatin [213]. These findings underscore the involvement of epigenetic mechanisms and circadian regulation.

CLOCK:BMAL1 mediated activation of CCGs has been shown to be coupled to circadian changes by histone acetylation at their promoters [214]. CLOCK also possesses intrinsic histone acetylase activity. Because CLOCK binds to E-box regions of DNA, HAT activity of CLOCK can selectively remodel chromatin at the promoters of CCGs [220]. HAT activity of CLOCK acetylates non-histone substrates, such as BMAL1, leading to facilitated CRY-dependent repression [221]. In addition, the transcription factor CLOCK has intrinsic histone acetyltransferase activity. CLOCK binds to H3K9 and K14 at the promoters of CCG [220]. HAT activity of CLOCK also acetylates non-histone substrates, such as its own binding partner, BMAL1 [221]. CLOCK specifically acetylates BMAL1 at a conserved residue, which enhances CRY-mediated transcriptional repression.

4.3. Connection among the Circadian Clock, Epigenetic Variation and Metabolism

Circadian clock genes and metabolic status have a connection. Circadian disruption caused by abnormal circadian melatonin secretion has been proposed to be the cause of obesity development. Hypothalamic obesity is obesity resulting from polyphagia and from increased body weight gain that emerges after extensive suprasellar operations to excise hypothalamic tumors. Patients with hypothalamic obesity display increases in morning and night salivary melatonin compared with controls [222]. Epigenetic marks in circadian rhythm genes are able to modulate metabolic functions. In human studies, rotating shift work has been found to be associated with many components of metabolic syndrome [223]. Long-term shift work results in hypomethylation of CLOCK and hypermethylation of CRY2. Hypoxia inducible factor 1 α (HIF1 α) is a part of the master CLOCK gene/protein interaction network that might modulate insulin resistance [224,225].

Another connection between the circadian clock, metabolism, and aging is the interaction between the circadian clock and SIRT1 [226]. SIRT1 is the only HDAC whose enzymatic activity is NAD⁺-dependent; thus, SIRT1 has been directly linked to the control of metabolism and aging [227]. Recently, SIRT1 has been introduced as a critical regulator of the circadian clock machinery [228,229]. The BMAL1:CLOCK complex and the BMAL1:CLOCK:PER2 complex interact with SIRT1. SIRT1 binds to the CLOCK:BMAL1 complex at clock gene promoters and deacetylates BMAL1 at the

Lys537 area [228–231]. In turn, SIRT1 is regulated by the circadian system. The *Nampt* gene is under the direct transcriptional control of the BMAL1:CLOCK complex. The expression of *nampt* and NAD⁺ levels demonstrate circadian oscillation, which suggests circadian control of SIRT1 activity [73,229,231,232]. SIRT1 may participate in this effect because SIRT1 and CLOCK variants have an effect on resistance to body weight loss that could be related to the human chronotype. Participants who carry minor alleles at SIRT1 and CLOCK loci displayed a high resistance to weight loss and a lower weekly weight loss rate than people who have the homozygotes for both major alleles [233]. By increasing the possibility of SIRT1, NAMPT and the circadian clock system in regulating metabolic status may lead to the development of a novel treatment for obesity.

4.4. Melatonin, Circadian Clock and Aging

Circadian clock dysfunction contributes to aging and to age-related pathologies. BMAL1-deficient mice develop a premature aging phenotype, characterized by multiple age-related abnormalities and an almost threefold reduction in lifespan [234]. The *Clock*^{-/-} mice exhibit an increased rate of inflammation, cataracts and a 15% reduction in longevity [235]. Although the lifespan of *Clock* and *Per2* mutated mice after exposure to non-lethal doses of ionizing irradiation have not been documented, these mice have a shorter lifespan and exhibit some senescence phenotypes [236,237]. In addition to the importance of the circadian clock in accelerating aging, the circadian clock also controls other systems known to be associated with aging, such as the control of metabolism, oxidative stress response, and DNA repair [188,238].

Age-related changes in the SCN may lead to circadian dysfunctions, such as decreased circadian neural activity [239], decreased amplitudes of the circadian body temperature rhythms [240], altered serotonin rhythms in the SCN [241], altered neuropeptide contents and GABAergic networks in the SCN [242], and altered SCN sensitivity [241,243,244]. Melatonin production, amplitude and its pulsatile release from the pineal gland decrease upon aging [245]. Disturbed circadian melatonin rhythm has profound effects on the health and well-being of the elderly subjects [246,247]. *Per2* and *Bmal1* disruption in mice has been compared to some workers with alterations in behavioral rhythms, to the development of malignant tumors, to metabolic syndrome [248,249] and to premature aging [250].

Melatonin receptors are present in the mammalian SCN, and circulating melatonin can reach the central SCN clock. This feedback is important in the long-term functioning of the circadian system, e.g., aging [207]. The presence of MT1 receptors in the SCN indicates that exogenous melatonin can affect circadian regulation. The differential effects of melatonin in restoring daily rhythms of serotonin [241], antioxidant enzymes and lipid peroxidation [243] have previously been reported. Moreover, aging results in differential alterations in daily rhythms of expression of various clock genes (*Per1*, *Per2*, *Cry1*, *Cry2* and *Bmal1*) in the SCN, and the therapeutic effects of melatonin in restoring such age-induced alterations have also been documented. The mRNA expressions of various clock genes in SCN in 3, 12 and 24 months showed that the circadian variation were due to age. In young rats (3 months), *Per1*mRNA expression peaked at zeitgeber time-6 (ZT-6), while *Per2*, *Cry1* and *rCry2* at ZT-12 and *Bmal1* peaked at ZT-18. The phases of circadian mRNA expression exhibited the change of daily rhythms of these genes. Melatonin administration for 11 days restored of the rhythm of *Per2*, *Cry1*, *Cry2* and *Bmal1* in 12-month, whereas, the fluctuation of *Cry1*, *Cry2* and *Bmal1* were

restored at 24 months old. The abolishment of fluctuation of these circadian genes may be due to the decrease of the SCN melatonin receptor number [251]. The difference of melatonin effect on each circadian gene in the progress of aging needs to be further studied.

4.5. Circadian Regulation and Autophagy

The diurnal variation in autophagy activities and the number of autophagic vacuoles found, vary during the day in many tissues [252–255]. The measurement of autophagic markers revealed that autophagy in the liver flux reached a maximal peak during the afternoon and declined to minimum during the dark period [256]. In the retina, autophagy was stimulated by light under constant conditions and obtained maximal responses during the late dark and early light phases [257]. Several genes in the autophagy pathways were expressed in an oscillate manner when exposed to varied nutrient conditions [258,259].

C/EBP β , which is a leucine zipper transcription factor, plays an important role in linking the circadian rhythm and autophagy gene expression. C/EBP β is expressed in a rhythmic manner and is regulated by the liver clock. C/EBP β stimulates autophagy gene expression and induces autophagic protein degradation in cultured hepatocytes. This transcription factor binds directly to the promoter regions of autophagy genes and then activates transcription [260,261]. Several lines of evidence demonstrate the roles of mTOR signaling in circadian clocks. In the SCN, mTOR activity displays robust circadian rhythms, and its rhythms are affected by light cues [262]. A genetic modification increasing mTOR activity displayed abnormal circadian rhythm with a longer period in *Drosophila* [263]. mTOR inhibitor treatment also decreases light-induced PER protein expression and helps modulate the phase shifts in behavior in animals [264]. Disrupting the circadian rhythm leads to many pathological conditions. Increasing the mTOR signaling pathway is associated with accelerated aging. In contrast, the circadian clock is one of the important systems for controlling autophagic activity [259]. Mice lacking *Bmal1* had elevated mTORC1 activity both *in vivo* and in cell culture [265]. Interestingly, the pharmacological inhibition of mTORC1 by rapamycin increased the lifespan of *Bmal1*^{-/-} mice by 50%. BMAL1 regulates the mTOR signaling pathway by acting as a negative regulator of mTORC1 signaling. These findings demonstrate the role of the circadian clock in regulating the mTOR signaling pathway in mammals.

4.6. Role of Melatonin and SIRT1 as Circadian Modulators in Memory Processing

Memory formation processes contribute to the circadian rhythms in vertebrate and invertebrate models [266]. One of the key problems during aging is memory impairment, which is one of the symptoms of Alzheimer's disease. Melatonin may improve memory processes during aging through SIRT1 and circadian modulation because melatonin increased hippocampal SIRT1 level and improved cognitive functions in total sleep deprivation models [105]. Moreover, memory formation is also controlled by circadian regulation. Evidence from one study indicates that functional clocks are present in many parts in the brain, including the hippocampus, suggesting the presence of an autonomous clock; *Per2* expression was found to be rhythmic in isolated hippocampi [267]. A time-of-day effect is observed in memory formation, thereby linking the circadian clock to this biological process [266]. Long-term potentiation (LTP) in the hippocampus has been demonstrated to undergo circadian

changes [268]. Moreover, mitogen-activated protein kinase (MAPK) phosphorylation displays rhythmicity in the hippocampus, and inhibiting this oscillation leads to impairment in the persistence of long-term memory [269].

An important function of the circadian clock is to synchronize different metabolic processes in an organism and to synchronize an organism to its environment to guarantee the optimal performance of different organ systems. The physiological processes controlled by the circadian clock include energy metabolism, sleep-wake cycles, hormone secretion, body temperature, locomotor activity, and visceral organ functions; all these mechanisms exhibit daily variations [270–273]. In humans, abnormal circadian clock rhythms can be found in individuals performing shift work and are expected to be the cause of neurodegeneration, metabolic syndromes, cardiovascular diseases and cancer [274].


The circadian acetylation function of SIRT1 has been described in aging and in neurodegeneration [275]. SIRT1 was shown to deacetylate and coactivate retinoic acid receptor β (RAR β), which leads to activation of the transcription of *Adam10*, which is a gene that encodes α -secretase [276]. Cleavage of the amyloid precursor protein by α -secretase prevents the production of the toxic amyloid β peptides that cause Alzheimer's disease. Thus, SIRT1 appears to have a neuroprotective role [276]. SIRT1 also deacetylates tau and prevents tauopathy that is evident in several neurodegenerative diseases [277]. Moreover, treatment with the SIRT1 activator resveratrol or ectopic SIRT1 expression was shown to prevent neuronal cell death [278].

Recent studies have reported that SIRT1 also plays a major role in synaptic plasticity and memory formation. Brain-specific SIRT1 mutant mice or SIRT1 whole-body knockout mice displayed deficits in learning and memory [279,280]. Brain-specific SIRT1 mutant mice exhibited lower levels of CREB protein expression in the hippocampus. CREB expression was found to be downregulated by a microRNA, miR-134. SIRT1 negatively regulates miR-134 expression, thus, in turn, regulating CREB expression. miR-134 overexpression in the hippocampus mimics the loss of SIRT1, whereas knocking down miR-134 in the hippocampus ameliorates memory defects in the SIRT1 mutant mice [65,279].

5. Conclusions

In this review, we have discussed age-related changes in the normal nervous system that occur because of the mechanisms of energy metabolism. Melatonin plays a major role in regulating the following processes: 1. the circadian rhythm, including several clock genes (*Per1*, *Per2*, *Nampt*, *CLOCK*, and *BMAL1*); 2. epigenetics, including sirtuins and FoxOs; and 3. autophagy. Melatonin regulates several molecules and signaling pathways that sense and influence energy metabolism, including insulin/IGF1, and PI3K/Akt. These pathways regulate normal nervous system aging. Age-related neuronal energy deficits contribute to the pathogenesis of several neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease. The anti-aging properties of melatonin regulate energy metabolism, leading to longevity (Figure 1). A better understanding molecular aging and anti-aging mechanisms is required to increase lifespan under healthy conditions, particularly to improve cognitive functions.

Figure 1. Mechanism of melatonin in controlling normal nervous system aging, neuropathological aging and longevity. The multiple mechanisms of action of melatonin include the following: 1. regulating the circadian rhythm, including several clock genes (*Per1*, *Per2*, *Nampt*, CLOCK, and BMAL1); 2. epigenetics, including sirtuins and FoxOs (forkhead box O); and 3. autophagy, including mTOR (mammalian target of rapamycin) and Atg (autophagy-related proteins). Melatonin regulates several molecules and signaling pathways that sense and influence energy metabolism, including insulin/IGF1, Akt (protein kinase B), and PI3K (phosphoinositide 3 kinase). These pathways regulate normal nervous system aging. Age-related neuronal energy deficits contribute to the pathogenesis of several neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease. The anti-aging properties of melatonin regulate energy metabolism, leading to longevity.



Acknowledgments

The financial support from the Thailand Research Fund (grant No.DPG5780001) and Mahidol University to PG is gratefully acknowledged.

Conflicts of Interest

The authors declare no conflict of interest.

References

1. Hardeland, R. Melatonin, hormone of darkness and more: Occurrence, control mechanisms, actions and bioactive metabolites. *Cell. Mol. Life Sci.* **2008**, *65*, 2001–2018.

2. Reiter, R.J. Melatonin: The chemical expression of darkness. *Mol. Cell Endocrinol.* **1991**, *79*, C153–C158.
3. Ostrowska, Z.; Kos-Kudla, B.; Swietochowska, E.; Marek, B.; Kajdaniuk, D.; Ciesielska-Kopacz, N. Influence of pinealectomy and long-term melatonin administration on GH-IGF-I axis function in male rats. *Neuro. Endocrinol. Lett.* **2001**, *22*, 255–262.
4. Vriend, J.; Sheppard, M.S.; Borer, K.T. Melatonin increases serum growth hormone and insulin-like growth factor I (IGF-I) levels in male Syrian hamsters via hypothalamic neurotransmitters. *Growth Dev. Aging* **1990**, *54*, 165–171.
5. Gutierrez-Cuesta, J.; Tajés, M.; Jimenez, A.; Coto-Montes, A.; Camins, A.; Pallas, M. Evaluation of potential pro-survival pathways regulated by melatonin in a murine senescence model. *J. Pineal Res.* **2008**, *45*, 497–505.
6. Tajés, M.; Gutierrez-Cuesta, J.; Ortuno-Sahagun, D.; Camins, A.; Pallas, M. Anti-aging properties of melatonin in an *in vitro* murine senescence model: Involvement of the sirtuin 1 pathway. *J. Pineal Res.* **2009**, *47*, 228–237.
7. Cristofol, R.; Porquet, D.; Corpas, R.; Coto-Montes, A.; Serret, J.; Camins, A.; Pallas, M.; Sanfeliu, C. Neurons from senescence-accelerated SAMP8 mice are protected against frailty by the sirtuin 1 promoting agents melatonin and resveratrol. *J. Pineal Res.* **2012**, *52*, 271–281.
8. Spielman, L.J.; Little, J.P.; Klegeris, A. Inflammation and insulin/IGF-1 resistance as the possible link between obesity and neurodegeneration. *J. Neuroimmunol.* **2014**, *273*, 8–21.
9. Long, Y.C.; Tan, T.M.; Takao, I.; Tang, B.L. The biochemistry and cell biology of aging: Metabolic regulation through mitochondrial signaling. *Am. J. Physiol. Endocrinol. MeTab.* **2014**, *306*, E581–E591.
10. Yin, F.; Jiang, T.; Cadenas, E. Metabolic triad in brain aging: Mitochondria, insulin/IGF-1 signalling and JNK signalling. *Biochem. Soc. Trans.* **2013**, *41*, 101–105.
11. Huang, H.; Tindall, D.J. Dynamic FoxO transcription factors. *J. Cell Sci.* **2007**, *120*, 2479–2487.
12. Aberg, N.D.; Brywe, K.G.; Isgaard, J. Aspects of growth hormone and insulin-like growth factor-I related to neuroprotection, regeneration, and functional plasticity in the adult brain. *Sci. World J.* **2006**, *6*, 53–80.
13. Wada, A.; Yokoo, H.; Yanagita, T.; Kobayashi, H. New twist on neuronal insulin receptor signaling in health, disease, and therapeutics. *J. Pharmacol. Sci.* **2005**, *99*, 128–143.
14. Sun, L.Y.; Al-Regaiey, K.; Masternak, M.M.; Wang, J.; Bartke, A. Local expression of GH and IGF-1 in the hippocampus of GH-deficient long-lived mice. *Neurobiol. Aging* **2005**, *26*, 929–937.
15. Bartke, A. Impact of reduced insulin-like growth factor-1/insulin signaling on aging in mammals: Novel findings. *Aging Cell* **2008**, *7*, 285–290.
16. Simpson, J.E.; Ince, P.G.; Shaw, P.J.; Heath, P.R.; Raman, R.; Garwood, C.J.; Gelsthorpe, C.; Baxter, L.; Forster, G.; Matthews, F.E.; *et al.* Microarray analysis of the astrocyte transcriptome in the aging brain: Relationship to Alzheimer's pathology and APOE genotype. *Neurobiol. Aging* **2011**, *32*, 1795–1807.
17. O'Neill, C.; Kiely, A.P.; Coakley, M.F.; Manning, S.; Long-Smith, C.M. Insulin and IGF-1 signalling: Longevity, protein homeostasis and Alzheimer's disease. *Biochem. Soc. Trans.* **2012**, *40*, 721–727.

18. Westwood, A.J.; Beiser, A.; Decarli, C.; Harris, T.B.; Chen, T.C.; He, X.M.; Roubenoff, R.; Pikula, A.; Au, R.; Braverman, L.E.; *et al.* Insulin-like growth factor-1 and risk of Alzheimer dementia and brain atrophy. *Neurology* **2014**, *82*, 1613–1619.
19. Trueba-Saiz, A.; Cavada, C.; Fernandez, A.M.; Leon, T.; Gonzalez, D.A.; Fortea Ormaechea, J.; Lleo, A.; del Ser, T.; Nunez, A.; Torres-Aleman, I. Loss of serum IGF-I input to the brain as an early biomarker of disease onset in Alzheimer mice. *Transl. Psychiatry* **2013**, *3*, doi:10.1038/tp.2013.102.
20. De Bruijn, R.F.; Janssen, J.A.; Brugts, M.P.; van Duijn, C.M.; Hofman, A.; Koudstaal, P.J.; Ikram, M.A. Insulin-like growth factor-I receptor stimulating activity is associated with dementia. *J. Alzheimers Dis.* **2014**, *42*, 137–142.
21. Zemva, J.; Schubert, M. The role of neuronal insulin/insulin-like growth factor-1 signaling for the pathogenesis of Alzheimer's disease: Possible therapeutic implications. *CNS Neurol. Disord. Drug Targets* **2014**, *13*, 322–337.
22. Desai, G.; Zheng, C.; Geetha, T.; Mathews, S.T.; White, B.D.; Huggins, K.W.; Zizza, C.A.; Broderick, T.L.; Babu, J.R. The pancreas-brain axis: Insight into disrupted mechanisms associating type 2 diabetes and Alzheimer's disease. *J. Alzheimers Dis.* **2014**, *42*, 347–356.
23. Kim, J.H.; Choi, J.S.; Lee, B.H. PI3K/Akt and MAPK pathways evoke activation of FoxO transcription factor to undergo neuronal apoptosis in brain of the silkworm *Bombyx mori* (Lepidoptera: Bombycidae). *Cell Mol. Biol.* **2012**, *58* (Suppl.), OL1780–OL1785.
24. Cheng, Z.; White, M.F. Targeting Forkhead box O1 from the concept to metabolic diseases: Lessons from mouse models. *Antioxid. Redox Signal.* **2011**, *14*, 649–661.
25. Wu, X.; Kihara, T.; Akaike, A.; Niidome, T.; Sugimoto, H. PI3K/Akt/mTOR signaling regulates glutamate transporter 1 in astrocytes. *Biochem. Biophys. Res. Commun.* **2010**, *393*, 514–518.
26. Erren, T.C.; Reiter, R.J. A generalized theory of carcinogenesis due to chronodisruption. *Neuro Endocrinol. Lett.* **2008**, *29*, 815–821.
27. Jung, B.; Ahmad, N. Melatonin in cancer management: Progress and promise. *Cancer Res.* **2006**, *66*, 9789–9793.
28. Peyrot, F.; Ducrocq, C. Potential role of tryptophan derivatives in stress responses characterized by the generation of reactive oxygen and nitrogen species. *J. Pineal Res.* **2008**, *45*, 235–246.
29. Tan, D.X.; Manchester, L.C.; Terron, M.P.; Flores, L.J.; Reiter, R.J. One molecule, many derivatives: A never-ending interaction of melatonin with reactive oxygen and nitrogen species? *J. Pineal Res.* **2007**, *42*, 28–42.
30. Puchalski, S.S.; Green, J.N.; Rasmussen, D.D. Melatonin effect on rat body weight regulation in response to high-fat diet at middle age. *Endocrine* **2003**, *21*, 163–167.
31. Wolden-Hanson, T.; Mitton, D.R.; McCants, R.L.; Yellon, S.M.; Wilkinson, C.W.; Matsumoto, A.M.; Rasmussen, D.D. Daily melatonin administration to middle-aged male rats suppresses body weight, intraabdominal adiposity, and plasma leptin and insulin independent of food intake and total body fat. *Endocrinology* **2000**, *141*, 487–497.
32. She, M.; Deng, X.; Guo, Z.; Laudon, M.; Hu, Z.; Liao, D.; Hu, X.; Luo, Y.; Shen, Q.; Su, Z.; *et al.* NEU-P11, a novel melatonin agonist, inhibits weight gain and improves insulin sensitivity in high-fat/high-sucrose-fed rats. *Pharmacol. Res.* **2009**, *59*, 248–253.

33. Zanutta, M.M.; Seraphim, P.M.; Sumida, D.H.; Cipolla-Neto, J.; Machado, U.F. Calorie restriction reduces pinealectomy-induced insulin resistance by improving GLUT4 gene expression and its translocation to the plasma membrane. *J. Pineal Res.* **2003**, *35*, 141–148.
34. Peschke, E. Melatonin, endocrine pancreas and diabetes. *J. Pineal Res.* **2008**, *44*, 26–40.
35. Mantele, S.; Otway, D.T.; Middleton, B.; Bretschneider, S.; Wright, J.; Robertson, M.D.; Skene, D.J.; Johnston, J.D. Daily rhythms of plasma melatonin, but not plasma leptin or leptin mRNA, vary between lean, obese and type 2 diabetic men. *PLoS One* **2012**, *7*, e37123.
36. Srinivasan, V.; Ohta, Y.; Espino, J.; Pariente, J.A.; Rodriguez, A.B.; Mohamed, M.; Zakaria, R. Metabolic syndrome, its pathophysiology and the role of melatonin. *Recent Pat. Endocr. Metab. Immune Drug Discov.* **2013**, *7*, 11–25.
37. Piccinetti, C.C.; Migliarini, B.; Olivotto, I.; Simoniello, M.P.; Giorgini, E.; Carnevali, O. Melatonin and peripheral circuitries: Insights on appetite and metabolism in *Danio rerio*. *Zebrafish* **2013**, *10*, 275–282.
38. Marques, F.Z.; Markus, M.A.; Morris, B.J. The molecular basis of longevity, and clinical implications. *Maturitas* **2010**, *65*, 87–91.
39. Vaquero, A.; Reinberg, D. Calorie restriction and the exercise of chromatin. *Genes Dev.* **2009**, *23*, 1849–1869.
40. Berdichevsky, A.; Viswanathan, M.; Horvitz, H.R.; Guarente, L. *C. elegans* SIR-2.1 interacts with 14-3-3 proteins to activate DAF-16 and extend life span. *Cell* **2006**, *125*, 1165–1177.
41. Berryman, D.E.; Christiansen, J.S.; Johannsson, G.; Thorner, M.O.; Kopchick, J.J. Role of the GH/IGF-1 axis in lifespan and healthspan: Lessons from animal models. *Growth Horm. IGF Res.* **2008**, *18*, 455–471.
42. Hekimi, S.; Guarente, L. Genetics and the specificity of the aging process. *Science* **2003**, *299*, 1351–1354.
43. Weeks, K.R.; Dwyer, D.S.; Aamodt, E.J. Antipsychotic drugs activate the *C. elegans* Akt pathway via the DAF-2 insulin/IGF-1 receptor. *ACS Chem. Neurosci.* **2010**, *1*, 463–473.
44. Liang, R.; Khanna, A.; Muthusamy, S.; Li, N.; Sarojini, H.; Kopchick, J.J.; Masternak, M.M.; Bartke, A.; Wang, E. Post-transcriptional regulation of IGF1R by key microRNAs in long-lived mutant mice. *Aging Cell* **2011**, *10*, 1080–1088.
45. Swindell, W.R. Gene expression profiling of long-lived dwarf mice: Longevity-associated genes and relationships with diet, gender and aging. *BMC Genomics* **2007**, *8*, doi:10.1186/1471-2164-8-353.
46. Shimokawa, I.; Trindade, L.S. Dietary restriction and aging in rodents: A current view on its molecular mechanisms. *Aging Dis.* **2010**, *1*, 89–107.
47. Nishida, S.; Sato, R.; Murai, I.; Nakagawa, S. Effect of pinealectomy on plasma levels of insulin and leptin and on hepatic lipids in type 2 diabetic rats. *J. Pineal Res.* **2003**, *35*, 251–256.
48. Nduhirabandi, F.; du Toit, E.F.; Lochner, A. Melatonin and the metabolic syndrome: A tool for effective therapy in obesity-associated abnormalities? *Acta Physiol.* **2012**, *205*, 209–223.
49. Ge, D.; Dauchy, R.T.; Liu, S.; Zhang, Q.; Mao, L.; Dauchy, E.M.; Blasko, D.E.; Hill, S.M.; Rowan, B.G.; Brainard, G.C.; *et al.* Insulin and IGF1 enhance IL-17-induced chemokine expression through a GSK3B-dependent mechanism: A new target for melatonin's anti-inflammatory action. *J. Pineal Res.* **2013**, *55*, 377–387.

50. Nassar, E.; Mulligan, C.; Taylor, L.; Kerksick, C.; Galbreath, M.; Greenwood, M.; Kreider, R.; Willoughby, D.S. Effects of a single dose of *N*-Acetyl-5-methoxytryptamine (Melatonin) and resistance exercise on the growth hormone/IGF-1 axis in young males and females. *J. Int. Soc. Sports Nutr.* **2007**, *4*, doi:10.1186/1550-2783-4-14.
51. Koh, P.O. Melatonin prevents the injury-induced decline of Akt/forkhead transcription factors phosphorylation. *J. Pineal Res.* **2008**, *45*, 199–203.
52. Lee, S.H.; Chun, W.; Kong, P.J.; Han, J.A.; Cho, B.P.; Kwon, O.Y.; Lee, H.J.; Kim, S.S. Sustained activation of Akt by melatonin contributes to the protection against kainic acid-induced neuronal death in hippocampus. *J. Pineal Res.* **2006**, *40*, 79–85.
53. Tajés Orduna, M.; Pelegri Gabalda, C.; Vilaplana Hortensi, J.; Pallas Lliberia, M.; Camins Espuny, A. An evaluation of the neuroprotective effects of melatonin in an *in vitro* experimental model of age-induced neuronal apoptosis. *J. Pineal Res.* **2009**, *46*, 262–267.
54. Calvanese, V.; Lara, E.; Kahn, A.; Fraga, M.F. The role of epigenetics in aging and age-related diseases. *Ageing Res. Rev.* **2009**, *8*, 268–276.
55. Bandyopadhyay, D.; Medrano, E.E. The emerging role of epigenetics in cellular and organismal aging. *Exp. Gerontol.* **2003**, *38*, 1299–1307.
56. Munoz-Najar, U.; Sedivy, J.M. Epigenetic control of aging. *Antioxid. Redox Signal.* **2011**, *14*, 241–259.
57. Coppieters, N.; Dieriks, B.V.; Lill, C.; Faull, R.L.; Curtis, M.A.; Dragunow, M. Global changes in DNA methylation and hydroxymethylation in Alzheimer's disease human brain. *Neurobiol. Aging* **2014**, *35*, 1334–1344.
58. Dagnas, M.; Mons, N. Region- and age-specific patterns of histone acetylation related to spatial and cued learning in the water maze. *Hippocampus* **2013**, *23*, 581–591.
59. Dos Santos Sant' Anna, G.; Rostirola Elsner, V.; Moyses, F.; Reck Cechinel, L.; Agustini Lovatel, G.; Rodrigues Siqueira, I. Histone deacetylase activity is altered in brain areas from aged rats. *Neurosci. Lett.* **2013**, *556*, 152–154.
60. Sen, N. Epigenetic regulation of memory by acetylation and methylation of chromatin: Implications in neurological disorders, aging, and addiction. *Neuromolecul. Med.* **2014**, doi:10.1007/s12017-014-8306-x.
61. Wang, C.M.; Tsai, S.N.; Yew, T.W.; Kwan, Y.W.; Ngai, S.M. Identification of histone methylation multiplicities patterns in the brain of senescence-accelerated prone mouse 8. *Biogerontology* **2010**, *11*, 87–102.
62. Cosin-Tomas, M.; Alvarez-Lopez, M.J.; Sanchez-Roige, S.; Lalanza, J.F.; Bayod, S.; Sanfeliu, C.; Pallas, M.; Escorihuela, R.M.; Kaliman, P. Epigenetic alterations in hippocampus of SAMP8 senescent mice and modulation by voluntary physical exercise. *Front. Aging Neurosci.* **2014**, *6*, doi:10.1007/s12017-014-8306-x.
63. Dagnas, M.; Guillou, J.L.; Prevot, T.; Mons, N. HDAC inhibition facilitates the switch between memory systems in young but not aged mice. *J. Neurosci.* **2013**, *33*, 1954–1963.
64. Castellano, J.F.; Fletcher, B.R.; Patzke, H.; Long, J.M.; Sewal, A.; Kim, D.H.; Kelley-Bell, B.; Rapp, P.R. Reassessing the effects of histone deacetylase inhibitors on hippocampal memory and cognitive aging. *Hippocampus* **2014**, *24*, 1006–1016.

65. Tomas Pereira, I.; Coletta, C.E.; Perez, E.V.; Kim, D.H.; Gallagher, M.; Goldberg, I.G.; Rapp, P.R. CREB-binding protein levels in the rat hippocampus fail to predict chronological or cognitive aging. *Neurobiol. Aging* **2013**, *34*, 832–844.
66. Li, Q.; Xiao, H.; Isobe, K. Histone acetyltransferase activities of cAMP-regulated enhancer-binding protein and p300 in tissues of fetal, young, and old mice. *J. Gerontol. A Biol. Sci. Med. Sci.* **2002**, *57*, B93–B98.
67. Bousiges, O.; Vasconcelos, A.P.; Neidl, R.; Cosquer, B.; Herbeaux, K.; Panteleeva, I.; Loeffler, J.P.; Cassel, J.C.; Boutillier, A.L. Spatial memory consolidation is associated with induction of several lysine-acetyltransferase (histone acetyltransferase) expression levels and H2B/H4 acetylation-dependent transcriptional events in the rat hippocampus. *Neuropsychopharmacology* **2010**, *35*, 2521–2537.
68. Brown, R.; Imran, S.A.; Ur, E.; Wilkinson, M. Valproic acid and CEBP α -mediated regulation of adipokine gene expression in hypothalamic neurons and 3T3-L1 adipocytes. *Neuroendocrinology* **2008**, *88*, 25–34.
69. Hodgson, N.; Trivedi, M.; Muratore, C.; Li, S.; Deth, R. Soluble oligomers of amyloid- β cause changes in redox state, DNA methylation, and gene transcription by inhibiting EAAT3 mediated cysteine uptake. *J. Alzheimers Dis.* **2013**, *36*, 197–209.
70. Bardai, F.H.; Price, V.; Zaayman, M.; Wang, L.; D’Mello, S.R. Histone deacetylase-1 (HDAC1) is a molecular switch between neuronal survival and death. *J. Biol. Chem.* **2012**, *287*, 35444–35453.
71. Nakagawa, T.; Guarente, L. Sirtuins at a glance. *J. Cell Sci.* **2011**, *124*, 833–838.
72. Braidy, N.; Guillemin, G.J.; Mansour, H.; Chan-Ling, T.; Poljak, A.; Grant, R. Age related changes in NAD⁺ metabolism oxidative stress and Sirt1 activity in wistar rats. *PLoS One* **2011**, *6*, e19194.
73. Imai, S. Dissecting systemic control of metabolism and aging in the NAD World: The importance of SIRT1 and NAMPT-mediated NAD biosynthesis. *FEBS Lett.* **2011**, *585*, 1657–1662.
74. Zakhary, S.M.; Ayubcha, D.; Dileo, J.N.; Jose, R.; Leheste, J.R.; Horowitz, J.M.; Torres, G. Distribution analysis of deacetylase SIRT1 in rodent and human nervous systems. *Anat. Rec. Hoboken* **2010**, *293*, 1024–1032.
75. Sasaki, T.; Kitamura, T. Roles of FoxO1 and Sirt1 in the central regulation of food intake. *Endocr. J.* **2010**, *57*, 939–946.
76. Cakir, I.; Perello, M.; Lansari, O.; Messier, N.J.; Vaslet, C.A.; Nillni, E.A. Hypothalamic Sirt1 regulates food intake in a rodent model system. *PLoS One* **2009**, *4*, e8322.
77. Sasaki, T.; Kim, H.J.; Kobayashi, M.; Kitamura, Y.I.; Yokota-Hashimoto, H.; Shiuchi, T.; Minokoshi, Y.; Kitamura, T. Induction of hypothalamic Sirt1 leads to cessation of feeding via agouti-related peptide. *Endocrinology* **2010**, *151*, 2556–2566.
78. Greco, S.J.; Hamzelou, A.; Johnston, J.M.; Smith, M.A.; Ashford, J.W.; Tezapsidis, N. Leptin boosts cellular metabolism by activating AMPK and the sirtuins to reduce tau phosphorylation and β -amyloid in neurons. *Biochem. Biophys. Res. Commun.* **2011**, *414*, 170–174.

79. Dietrich, M.O.; Antunes, C.; Geliang, G.; Liu, Z.W.; Borok, E.; Nie, Y.; Xu, A.W.; Souza, D.O.; Gao, Q.; Diano, S.; *et al.* Agrp neurons mediate Sirt1's action on the melanocortin system and energy balance: Roles for Sirt1 in neuronal firing and synaptic plasticity. *J. Neurosci.* **2010**, *30*, 11815–11825.
80. Parmentier, F.; Lejeune, F.X.; Neri, C. Pathways to decoding the clinical potential of stress response FOXO-interaction networks for Huntington's disease: Of gene prioritization and context dependence. *Front. Aging Neurosci.* **2013**, *5*, doi:10.3389/fnagi.2013.00022.
81. Ro, S.H.; Liu, D.; Yeo, H.; Paik, J.H. FoxOs in neural stem cell fate decision. *Arch. Biochem. Biophys.* **2013**, *534*, 55–63.
82. Shimokawa, I.; Higami, Y. Leptin signaling and aging: Insight from caloric restriction. *Mech. Ageing Dev.* **2001**, *122*, 1511–1519.
83. Kim, D.H.; Zhang, T.; Lee, S.; Dong, H.H. FoxO6 in glucose metabolism (FoxO6). *J. Diabetes* **2013**, *5*, 233–240.
84. Chaves, I.; van der Horst, G.T.; Schellevis, R.; Nijman, R.M.; Koerkamp, M.G.; Holstege, F.C.; Smidt, M.P.; Hoekman, M.F. Insulin-FOXO3 signaling modulates circadian rhythms via regulation of clock transcription. *Curr. Biol.* **2014**, *24*, 1248–1255.
85. Lorna Moll; Schubert, M. The role of insulin and insulin-like growth factor-1/FoxO-mediated transcription for the pathogenesis of obesity-associated dementia. *Curr. Gerontol. Geriatr. Res.* **2012**, *2012*, 1–13.
86. Salih, D.A.; Rashid, A.J.; Colas, D.; de la Torre-Ubieta, L.; Zhu, R.P.; Morgan, A.A.; Santo, E.E.; Ucar, D.; Devarajan, K.; Cole, C.J.; *et al.* FoxO6 regulates memory consolidation and synaptic function. *Genes Dev.* **2012**, *26*, 2780–2801.
87. Exil, V.; Ping, L.; Yu, Y.; Chakraborty, S.; Caito, S.W.; Wells, K.S.; Karki, P.; Lee, E.; Aschner, M. Activation of MAPK and FoxO by manganese (Mn) in rat neonatal primary astrocyte cultures. *PLoS One* **2014**, *9*, e94753.
88. Akhter, R.; Sanphui, P.; Biswas, S.C. The essential role of p53-up-regulated modulator of apoptosis (Puma) and its regulation by FoxO3a transcription factor in β -amyloid-induced neuron death. *J. Biol. Chem.* **2014**, *289*, 10812–10822.
89. Pino, E.; Amamoto, R.; Zheng, L.; Cacquevel, M.; Sarria, J.C.; Knott, G.W.; Schneider, B.L. FOXO3 determines the accumulation of α -synuclein and controls the fate of dopaminergic neurons in the substantia nigra. *Hum. Mol. Genet.* **2014**, *23*, 1435–1452.
90. Mediavilla, M.D.; Sanchez-Barcelo, E.J.; Tan, D.X.; Manchester, L.; Reiter, R.J. Basic mechanisms involved in the anti-cancer effects of melatonin. *Curr. Med. Chem.* **2010**, *17*, 4462–4481.
91. Korkmaz, A.; Sanchez-Barcelo, E.J.; Tan, D.X.; Reiter, R.J. Role of melatonin in the epigenetic regulation of breast cancer. *Breast Cancer Res. Treat.* **2009**, *115*, 13–27.
92. Lee, S.E.; Kim, S.J.; Yoon, H.J.; Yu, S.Y.; Yang, H.; Jeong, S.I.; Hwang, S.Y.; Park, C.S.; Park, Y.S. Genome-wide profiling in melatonin-exposed human breast cancer cell lines identifies differentially methylated genes involved in the anticancer effect of melatonin. *J. Pineal Res.* **2013**, *54*, 80–88.

93. Nakamura, E.; Kozaki, K.; Tsuda, H.; Suzuki, E.; Pimkhaokham, A.; Yamamoto, G.; Irie, T.; Tachikawa, T.; Amagasa, T.; Inazawa, J.; *et al.* Frequent silencing of a putative tumor suppressor gene melatonin receptor 1 A (MTNR1A) in oral squamous-cell carcinoma. *Cancer Sci.* **2008**, *99*, 1390–1400.
94. Tiao, M.M.; Huang, L.T.; Chen, C.J.; Sheen, J.M.; Tain, Y.L.; Chen, C.C.; Kuo, H.C.; Huang, Y.H.; Tang, K.S.; Chu, E.W.; *et al.* Melatonin in the Regulation of Liver Steatosis following Prenatal Glucocorticoid Exposure. *Biomed. Res. Int.* **2014**, *2014*, doi:10.1155/2014/942172.
95. Tain, Y.L.; Chen, C.C.; Sheen, J.M.; Yu, H.R.; Tiao, M.M.; Kuo, H.C.; Huang, L.T. Melatonin attenuates prenatal dexamethasone-induced blood pressure increase in a rat model. *J. Am. Soc. Hypertens.* **2014**, *8*, 216–226.
96. Sharma, R.; Ottenhof, T.; Rzeczowska, P.A.; Niles, L.P. Epigenetic targets for melatonin: Induction of histone H3 hyperacetylation and gene expression in C17.2 neural stem cells. *J. Pineal Res.* **2008**, *45*, 277–284.
97. Kim, B.; Rincon Castro, L.M.; Jawed, S.; Niles, L.P. Clinically relevant concentrations of valproic acid modulate melatonin MT(1) receptor, HDAC and MeCP2 mRNA expression in C6 glioma cells. *Eur. J. Pharmacol.* **2008**, *589*, 45–48.
98. Wang, J.; Xiao, X.; Zhang, Y.; Shi, D.; Chen, W.; Fu, L.; Liu, L.; Xie, F.; Kang, T.; Huang, W.; *et al.* Simultaneous modulation of COX-2, p300, Akt, and Apaf-1 signaling by melatonin to inhibit proliferation and induce apoptosis in breast cancer cells. *J. Pineal Res.* **2012**, *53*, 77–90.
99. Shi, D.; Xiao, X.; Wang, J.; Liu, L.; Chen, W.; Fu, L.; Xie, F.; Huang, W.; Deng, W. Melatonin suppresses proinflammatory mediators in lipopolysaccharide-stimulated CRL1999 cells via targeting MAPK, NF- κ B, c/EBP β , and p300 signaling. *J. Pineal Res.* **2012**, *53*, 154–165.
100. Permpoonputtana, K.; Govitrapong, P. The anti-inflammatory effect of melatonin on methamphetamine-induced proinflammatory mediators in human neuroblastoma dopamine SH-SY5Y cell lines. *Neurotox. Res.* **2013**, *23*, 189–199.
101. Wang, Z.; Ma, C.; Meng, C.J.; Zhu, G.Q.; Sun, X.B.; Huo, L.; Zhang, J.; Liu, H.X.; He, W.C.; Shen, X.M.; *et al.* Melatonin activates the Nrf2-ARE pathway when it protects against early brain injury in a subarachnoid hemorrhage model. *J. Pineal Res.* **2012**, *53*, 129–137.
102. Negi, G.; Kumar, A.; Sharma, S.S. Melatonin modulates neuroinflammation and oxidative stress in experimental diabetic neuropathy: Effects on NF- κ B and Nrf2 cascades. *J. Pineal Res.* **2011**, *50*, 124–131.
103. Sun, Z.; Chin, Y.E.; Zhang, D.D. Acetylation of Nrf2 by p300/CBP augments promoter-specific DNA binding of Nrf2 during the antioxidant response. *Mol. Cell Biol.* **2009**, *29*, 2658–2672.
104. Korkmaz, A.; Rosales-Corral, S.; Reiter, R.J. Gene regulation by melatonin linked to epigenetic phenomena. *Gene* **2012**, *503*, 1–11.
105. Chang, H.M.; Wu, U.I.; Lan, C.T. Melatonin preserves longevity protein (sirtuin 1) expression in the hippocampus of total sleep-deprived rats. *J. Pineal Res.* **2009**, *47*, 211–220.
106. Jung-Hynes, B.; Schmit, T.L.; Reagan-Shaw, S.R.; Siddiqui, I.A.; Mukhtar, H.; Ahmad, N. Melatonin, a novel Sirt1 inhibitor, imparts antiproliferative effects against prostate cancer *in vitro* in culture and *in vivo* in TRAMP model. *J. Pineal Res.* **2011**, *50*, 140–149.
107. Jung-Hynes, B.; Reiter, R.J.; Ahmad, N. Sirtuins, melatonin and circadian rhythms: Building a bridge between aging and cancer. *J. Pineal Res.* **2010**, *48*, 9–19.

108. Cheng, Y.; Cai, L.; Jiang, P.; Wang, J.; Gao, C.; Feng, H.; Wang, C.; Pan, H.; Yang, Y. SIRT1 inhibition by melatonin exerts antitumor activity in human osteosarcoma cells. *Eur. J. Pharmacol.* **2013**, *715*, 219–229.
109. Tan, D.X.; Manchester, L.C.; Sainz, R.M.; Mayo, J.C.; Leon, J.; Hardeland, R.; Poeggeler, B.; Reiter, R.J. Interactions between melatonin and nicotinamide nucleotide: NADH preservation in cells and in cell-free systems by melatonin. *J. Pineal Res.* **2005**, *39*, 185–194.
110. Swerdlow, R.H. Brain aging, Alzheimer's disease, and mitochondria. *Biochim. Biophys. Acta* **2011**, *1812*, 1630–1639.
111. Duan, W. Sirtuins: From metabolic regulation to brain aging. *Front. Aging Neurosci.* **2013**, *5*, doi:10.3389/fnagi.2013.00036.
112. Mizushima, N.; Levine, B.; Cuervo, A.M.; Klionsky, D.J. Autophagy fights disease through cellular self-digestion. *Nature* **2008**, *451*, 1069–1075.
113. Inoki, K.; Corradetti, M.N.; Guan, K.L. Dysregulation of the TSC-mTOR pathway in human disease. *Nat. Genet.* **2005**, *37*, 19–24.
114. Todde, V.; Veenhuis, M.; van der Klei, I.J. Autophagy: Principles and significance in health and disease. *Biochim. Biophys. Acta* **2009**, *1792*, 3–13.
115. Shang, Y.C.; Chong, Z.Z.; Wang, S.; Maiese, K. Tuberosclerosis protein 2 (TSC2) modulates CCN4 cytoprotection during apoptotic amyloid toxicity in microglia. *Curr. Neurovasc. Res.* **2013**, *10*, 29–38.
116. Vellai, T.; Takacs-Vellai, K.; Zhang, Y.; Kovacs, A.L.; Orosz, L.; Muller, F. Genetics: Influence of TOR kinase on lifespan in *C. elegans*. *Nature* **2003**, *426*, doi:10.1038/426620a.
117. Levine, B.; Klionsky, D.J. Development by self-digestion: Molecular mechanisms and biological functions of autophagy. *Dev. Cell* **2004**, *6*, 463–477.
118. Rajawat, Y.S.; Bossis, I. Autophagy in aging and in neurodegenerative disorders. *Hormones* **2008**, *7*, 46–61.
119. Jia, K.; Hart, A.C.; Levine, B. Autophagy genes protect against disease caused by polyglutamine expansion proteins in *Caenorhabditis elegans*. *Autophagy* **2007**, *3*, 21–25.
120. Melendez, A.; Tallozy, Z.; Seaman, M.; Eskelinen, E.L.; Hall, D.H.; Levine, B. Autophagy genes are essential for dauer development and life-span extension in *C. elegans*. *Science* **2003**, *301*, 1387–1391.
121. Nixon R.A. Autophagy in neurodegenerative disease: Friend, foe or turncoat? *Trends Neurosci.* **2006**, *29*, 528–535.
122. Donati, A. The involvement of macroautophagy in aging and anti-aging interventions. *Mol. Asp. Med.* **2006**, *27*, 455–470.
123. Lionaki, E.; Markaki, M.; Tavernarakis, N. Autophagy and ageing: Insights from invertebrate model organisms. *Ageing Res. Rev.* **2013**, *12*, 413–428.
124. Low, P.; Varga, A.; Pircs, K.; Nagy, P.; Szatmari, Z.; Sass, M.; Juhasz, G. Impaired proteasomal degradation enhances autophagy via hypoxia signaling in *Drosophila*. *BMC Cell Biol.* **2013**, *14*, doi:10.1186/1471-2121-14-29.
125. Shibata, M.; Lu, T.; Furuya, T.; Degtarev, A.; Mizushima, N.; Yoshimori, T.; MacDonald, M.; Yankner, B.; Yuan, J. Regulation of intracellular accumulation of mutant Huntingtin by Beclin 1. *J. Biol. Chem.* **2006**, *281*, 14474–14485.

126. Gupta, V.K.; Scheunemann, L.; Eisenberg, T.; Mertel, S.; Bhukel, A.; Koemans, T.S.; Kramer, J.M.; Liu, K.S.; Schroeder, S.; Stunnenberg, H.G.; *et al.* Restoring polyamines protects from age-induced memory impairment in an autophagy-dependent manner. *Nat. Neurosci.* **2013**, *16*, 1453–1460.
127. Orr, M.E.; Oddo, S. Autophagic/lysosomal dysfunction in Alzheimer's disease. *Alzheimers Res. Ther.* **2013**, *5*, doi:10.1186/alzrt217.
128. Hardy, J.; Selkoe, D.J. The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. *Science* **2002**, *297*, 353–356.
129. Bokov, A.F.; Garg, N.; Ikeno, Y.; Thakur, S.; Musi, N.; DeFronzo, R.A.; Zhang, N.; Erickson, R.C.; Gelfond, J.; Hubbard, G.B.; *et al.* Does reduced IGF-1R signaling in *Igflr*^{+/-} mice alter aging? *PLoS One* **2011**, *6*, e26891.
130. Toth, M.L.; Sigmond, T.; Borsos, E.; Barna, J.; Erdelyi, P.; Takacs-Vellai, K.; Orosz, L.; Kovacs, A.L.; Csikos, G.; Sass, M.; *et al.* Longevity pathways converge on autophagy genes to regulate life span in *Caenorhabditis elegans*. *Autophagy* **2008**, *4*, 330–338.
131. Ghosh, H.S.; McBurney, M.; Robbins, P.D. SIRT1 negatively regulates the mammalian target of rapamycin. *PLoS One* **2010**, *5*, e9199.
132. Wu, Y.; Li, X.; Zhu, J.X.; Xie, W.; Le, W.; Fan, Z.; Jankovic, J.; Pan, T. Resveratrol-activated AMPK/SIRT1/autophagy in cellular models of Parkinson's disease. *Neurosignals* **2011**, *19*, 163–174.
133. Canto, C.; Gerhart-Hines, Z.; Feige, J.N.; Lagouge, M.; Noriega, L.; Milne, J.C.; Elliott, P.J.; Puigserver, P.; Auwerx, J. AMPK regulates energy expenditure by modulating NAD⁺ metabolism and SIRT1 activity. *Nature* **2009**, *458*, 1056–1060.
134. Lee, I.H.; Cao, L.; Mostoslavsky, R.; Lombard, D.B.; Liu, J.; Bruns, N.E.; Tsokos, M.; Alt, F.W.; Finkel, T. A role for the NAD-dependent deacetylase Sirt1 in the regulation of autophagy. *Proc. Natl. Acad. Sci. USA* **2008**, *105*, 3374–3379.
135. Baur, J.A.; Pearson, K.J.; Price, N.L.; Jamieson, H.A.; Lerin, C.; Kalra, A.; Prabhu, V.V.; Allard, J.S.; Lopez-Lluch, G.; Lewis, K.; *et al.* Resveratrol improves health and survival of mice on a high-calorie diet. *Nature* **2006**, *444*, 337–342.
136. Jeong, H.; Then, F.; Melia, T.J., Jr.; Mazzulli, J.R.; Cui, L.; Savas, J.N.; Voisine, C.; Paganetti, P.; Tanese, N.; Hart, A.C.; *et al.* Acetylation targets mutant huntingtin to autophagosomes for degradation. *Cell* **2009**, *137*, 60–72.
137. Lin, S.Y.; Li, T.Y.; Liu, Q.; Zhang, C.; Li, X.; Chen, Y.; Zhang, S.M.; Lian, G.; Ruan, K.; Wang, Z.; *et al.* Protein phosphorylation-acetylation cascade connects growth factor deprivation to autophagy. *Autophagy* **2012**, *8*, 1385–1386.
138. Lin, S.Y.; Li, T.Y.; Liu, Q.; Zhang, C.; Li, X.; Chen, Y.; Zhang, S.M.; Lian, G.; Ruan, K.; Wang, Z.; *et al.* GSK3-TIP60-ULK1 signaling pathway links growth factor deprivation to autophagy. *Science* **2012**, *336*, 477–481.
139. Lee, I.H.; Finkel, T. Regulation of autophagy by the p300 acetyltransferase. *J. Biol. Chem.* **2009**, *284*, 6322–6328.
140. Suzuki, M.; Bartlett, J.D. Sirtuin1 and autophagy protect cells from fluoride-induced cell stress. *Biochim. Biophys. Acta* **2014**, *1842*, 245–255.

141. Chen, J.; Zhou, Y.; Mueller-Steiner, S.; Chen, L.F.; Kwon, H.; Yi, S.; Mucke, L.; Gan, L. SIRT1 protects against microglia-dependent amyloid- β toxicity through inhibiting NF- κ B signaling. *J. Biol. Chem.* **2005**, *280*, 40364–40374.
142. Mukherjee, S.; Ray, D.; Lekli, I.; Bak, I.; Tosaki, A.; Das, D.K. Effects of Longevinex (modified resveratrol) on cardioprotection and its mechanisms of action. *Can. J. Physiol. Pharmacol.* **2010**, *88*, 1017–1025.
143. Medema, R.H.; Jaattela, M. Cytosolic FoxO1: Alive and killing. *Nat. Cell Biol.* **2010**, *12*, 642–643.
144. Ng, F.; Tang, B.L. Sirtuins' modulation of autophagy. *J. Cell Physiol.* **2013**, *228*, 2262–2270.
145. Xu, L.; Kanasaki, M.; He, J.; Kitada, M.; Nagao, K.; Jinzu, H.; Noguchi, Y.; Maegawa, H.; Kanasaki, K.; Koya, D. Ketogenic essential amino acids replacement diet ameliorated hepatosteatosis with altering autophagy-associated molecules. *Biochim. Biophys. Acta* **2013**, *1832*, 1605–1612.
146. Hariharan, N.; Maejima, Y.; Nakae, J.; Paik, J.; Depinho, R.A.; Sadoshima, J. Deacetylation of FoxO by Sirt1 plays an essential role in mediating starvation-induced autophagy in cardiac myocytes. *Circ. Res.* **2010**, *107*, 1470–1482.
147. Lee, Y.; Lee, H.Y.; Gustafsson, A.B. Regulation of autophagy by metabolic and stress signaling pathways in the heart. *J. Cardiovasc. Pharmacol.* **2012**, *60*, 118–124.
148. Luo, L.; Lu, A.M.; Wang, Y.; Hong, A.; Chen, Y.; Hu, J.; Li, X.; Qin, Z.H. Chronic resistance training activates autophagy and reduces apoptosis of muscle cells by modulating IGF-1 and its receptors, Akt/mTOR and Akt/FOXO3a signaling in aged rats. *Exp. Gerontol.* **2013**, *48*, 427–436.
149. Sengupta, A.; Molkenin, J.D.; Yutzey, K.E. FoxO transcription factors promote autophagy in cardiomyocytes. *J. Biol. Chem.* **2009**, *284*, 28319–28331.
150. Park, K.J.; Lee, S.H.; Lee, C.H.; Jang, J.Y.; Chung, J.; Kwon, M.H.; Kim, Y.S. Upregulation of Beclin-1 expression and phosphorylation of Bcl-2 and p53 are involved in the JNK-mediated autophagic cell death. *Biochem. Biophys. Res. Commun.* **2009**, *382*, 726–729.
151. Samara, C.; Syntichaki, P.; Tavernarakis, N. Autophagy is required for necrotic cell death in *Caenorhabditis elegans*. *Cell Death Differ.* **2008**, *15*, 105–112.
152. Wang, S.; Chong, Z.Z.; Shang, Y.C.; Maiese, K. WISP1 neuroprotection requires FoxO3a post-translational modulation with autoregulatory control of SIRT1. *Curr. Neurovasc. Res.* **2013**, *10*, 54–69.
153. Fontana, L.; Partridge, L.; Longo, V.D. Extending healthy life span—From yeast to humans. *Science* **2010**, *328*, 321–326.
154. Speakman, J.R.; Mitchell, S.E. Caloric restriction. *Mol. Asp. Med.* **2011**, *32*, 159–221.
155. Shi, L.; Adams, M.M.; Linville, M.C.; Newton, I.G.; Forbes, M.E.; Long, A.B.; Riddle, D.R.; Brunso-Bechtold, J.K. Caloric restriction eliminates the aging-related decline in NMDA and AMPA receptor subunits in the rat hippocampus and induces homeostasis. *Exp. Neurol.* **2007**, *206*, 70–79.
156. Fontan-Lozano, A.; Saez-Cassanelli, J.L.; Inda, M.C.; de los Santos-Arteaga, M.; Sierra-Dominguez, S.A.; Lopez-Lluch, G.; Delgado-Garcia, J.M.; Carrion, A.M. Caloric restriction increases learning consolidation and facilitates synaptic plasticity through mechanisms dependent on NR2B subunits of the NMDA receptor. *J. Neurosci.* **2007**, *27*, 10185–10195.

157. Komatsu, T.; Chiba, T.; Yamaza, H.; Yamashita, K.; Shimada, A.; Hoshiyama, Y.; Henmi, T.; Ohtani, H.; Higami, Y.; de Cabo, R.; *et al.* Manipulation of caloric content but not diet composition, attenuates the deficit in learning and memory of senescence-accelerated mouse strain P8. *Exp. Gerontol.* **2008**, *43*, 339–346.
158. Halagappa, V.K.; Guo, Z.; Pearson, M.; Matsuoka, Y.; Cutler, R.G.; Laferla, F.M.; Mattson, M.P. Intermittent fasting and caloric restriction ameliorate age-related behavioral deficits in the triple-transgenic mouse model of Alzheimer's disease. *Neurobiol. Dis.* **2007**, *26*, 212–220.
159. Wu, P.; Shen, Q.; Dong, S.; Xu, Z.; Tsien, J.Z.; Hu, Y. Calorie restriction ameliorates neurodegenerative phenotypes in forebrain-specific presenilin-1 and presenilin-2 double knockout mice. *Neurobiol. Aging* **2008**, *29*, 1502–1511.
160. Rotermund, C.; Truckenmuller, F.M.; Schell, H.; Kahle, P.J. Diet-induced obesity accelerates the onset of terminal phenotypes in α -synuclein transgenic mice. *J. Neurochem.* **2014**, doi:10.1111/jnc.12813.
161. Morris, J.K.; Bomhoff, G.L.; Stanford, J.A.; Geiger, P.C. Neurodegeneration in an animal model of Parkinson's disease is exacerbated by a high-fat diet. *Am. J. Physiol. Regul. Integr. Comp. Physiol.* **2010**, *299*, R1082–R1090.
162. Hars, E.S.; Qi, H.; Ryazanov, A.G.; Jin, S.; Cai, L.; Hu, C.; Liu, L.F. Autophagy regulates ageing in *C. elegans*. *Autophagy* **2007**, *3*, 93–95.
163. Pattingre, S.; Espert, L.; Biard-Piechaczyk, M.; Codogno, P. Regulation of macroautophagy by mTOR and Beclin 1 complexes. *Biochimie* **2008**, *90*, 313–323.
164. Kaeberlein, M.; Powers, R.W., 3rd; Steffen, K.K.; Westman, E.A.; Hu, D.; Dang, N.; Kerr, E.O.; Kirkland, K.T.; Fields, S.; Kennedy, B.K. Regulation of yeast replicative life span by TOR and Sch9 in response to nutrients. *Science* **2005**, *310*, 1193–1196.
165. Sekito, T.; Kawamata, T.; Ichikawa, R.; Suzuki, K.; Ohsumi, Y. Atg17 recruits Atg9 to organize the pre-autophagosomal structure. *Genes Cells* **2009**, *14*, 525–538.
166. Morselli, E.; Maiuri, M.C.; Markaki, M.; Megalou, E.; Pasparaki, A.; Palikaras, K.; Criollo, A.; Galluzzi, L.; Malik, S.A.; Vitale, I.; *et al.* Caloric restriction and resveratrol promote longevity through the Sirtuin-1-dependent induction of autophagy. *Cell Death Dis.* **2010**, *1*, doi:10.1038/cddis.2009.8.
167. Caballero, B.; Coto-Montes, A. An insight into the role of autophagy in cell responses in the aging and neurodegenerative brain. *Histol. Histopathol.* **2012**, *27*, 263–275.
168. Levine, B.; Mizushima, N.; Virgin, H.W. Autophagy in immunity and inflammation. *Nature* **2011**, *469*, 323–335.
169. Virgin, H.W.; Levine, B. Autophagy genes in immunity. *Nat. Immunol.* **2009**, *10*, 461–470.
170. Djavaheri-Mergny, M.; Amelotti, M.; Mathieu, J.; Besancon, F.; Bauvy, C.; Souquere, S.; Pierron, G.; Codogno, P. NF- κ B activation represses tumor necrosis factor- α -induced autophagy. *J. Biol. Chem.* **2006**, *281*, 30373–30382.
171. Schlottmann, S.; Buback, F.; Stahl, B.; Meierhenrich, R.; Walter, P.; Georgieff, M.; Senftleben, U. Prolonged classical NF- κ B activation prevents autophagy upon *E. coli* stimulation *in vitro*: A potential resolving mechanism of inflammation. *Mediators Inflamm.* **2008**, *2008*, doi:10.1155/2008/725854.

172. Salminen, A.; Hyttinen, J.M.; Kauppinen, A.; Kaarniranta, K. Context-dependent regulation of autophagy by IKK-NF- κ B signaling: Impact on the aging process. *Int. J. Cell Biol.* **2012**, *2012*, doi:10.1155/2012/849541.
173. Salminen, A.; Kaarniranta, K.; Kauppinen, A. Beclin 1 interactome controls the crosstalk between apoptosis, autophagy and inflammasome activation: Impact on the aging process. *Ageing Res. Rev.* **2013**, *12*, 520–534.
174. Dan, H.C.; Cooper, M.J.; Cogswell, P.C.; Duncan, J.A.; Ting, J.P.; Baldwin, A.S. Akt-dependent regulation of NF- κ B is controlled by mTOR and Raptor in association with IKK. *Genes Dev.* **2008**, *22*, 1490–1500.
175. Lee, D.F.; Kuo, H.P.; Chen, C.T.; Wei, Y.; Chou, C.K.; Hung, J.Y.; Yen, C.J.; Hung, M.C. IKK β suppression of TSC1 function links the mTOR pathway with insulin resistance. *Int. J. Mol. Med.* **2008**, *22*, 633–638.
176. Lee, D.F.; Kuo, H.P.; Chen, C.T.; Hsu, J.M.; Chou, C.K.; Wei, Y.; Sun, H.L.; Li, L.Y.; Ping, B.; Huang, W.C.; *et al.* IKK β suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway. *Cell* **2007**, *130*, 440–455.
177. Nivon, M.; Richet, E.; Codogno, P.; Arrigo, A.P.; Kretz-Remy, C. Autophagy activation by NF- κ B is essential for cell survival after heat shock. *Autophagy* **2009**, *5*, 766–783.
178. Herranz, D.; Munoz-Martin, M.; Canamero, M.; Mulero, F.; Martinez-Pastor, B.; Fernandez-Capetillo, O.; Serrano, M. Sirt1 improves healthy ageing and protects from metabolic syndrome-associated cancer. *Nat. Commun.* **2010**, *1*, doi:10.1038/ncomms1001.
179. Yang, H.; Zhang, W.; Pan, H.; Feldser, H.G.; Lainez, E.; Miller, C.; Leung, S.; Zhong, Z.; Zhao, H.; Sweitzer, S.; *et al.* SIRT1 activators suppress inflammatory responses through promotion of p65 deacetylation and inhibition of NF- κ B activity. *PLoS One* **2012**, *7*, e46364.
180. Polyakova, O.; Borman, S.; Grimley, R.; Vamathevan, J.; Hayes, B.; Solari, R. Identification of novel interacting partners of Sirtuin6. *PLoS One* **2012**, *7*, e51555.
181. Yeung, F.; Hoberg, J.E.; Ramsey, C.S.; Keller, M.D.; Jones, D.R.; Frye, R.A.; Mayo, M.W. Modulation of NF- κ B-dependent transcription and cell survival by the SIRT1 deacetylase. *EMBO J.* **2004**, *23*, 2369–2380.
182. Rothgiesser, K.M.; Erener, S.; Waibel, S.; Luscher, B.; Hottiger, M.O. SIRT2 regulates NF- κ B dependent gene expression through deacetylation of p65 Lys310. *J. Cell Sci.* **2010**, *123*, 4251–4258.
183. Kawahara, T.L.; Michishita, E.; Adler, A.S.; Damian, M.; Berber, E.; Lin, M.; McCord, R.A.; Ongaigui, K.C.; Boxer, L.D.; Chang, H.Y.; *et al.* SIRT6 links histone H3 lysine 9 deacetylation to NF- κ B-dependent gene expression and organismal life span. *Cell* **2009**, *136*, 62–74.
184. Klongpanichapak, S.; Phansuwan-Pujito, P.; Ebadi, M.; Govitrapong, P. Melatonin protects SK-N-SH neuroblastoma cells from amphetamine-induced neurotoxicity. *J. Pineal Res.* **2007**, *43*, 65–73.
185. Klongpanichapak, S.; Phansuwan-Pujito, P.; Ebadi, M.; Govitrapong, P. Melatonin inhibits amphetamine-induced increase in α -synuclein and decrease in phosphorylated tyrosine hydroxylase in SK-N-SH cells. *Neurosci. Lett.* **2008**, *436*, 309–313.

186. Kongsuphol, P.; Mukda, S.; Nopparat, C.; Villarroel, A.; Govitrapong, P. Melatonin attenuates methamphetamine-induced deactivation of the mammalian target of rapamycin signaling to induce autophagy in SK-N-SH cells. *J. Pineal Res.* **2009**, *46*, 199–206.
187. Shimizu S.; Kanaseki T.; Mizushima N.; Mizuta T.; Arakawa-Kobayashi S.; Thompson, C.B.; Tsujimoto, Y. Role of Bcl-2 family proteins in a non-apoptotic programmed cell death dependent on autophagy genes. *Nat. Cell Biol.* **2004**, *6*, 1121–1128.
188. Khapre, R.V.; Samsa, W.E.; Kondratov, R.V. Circadian regulation of cell cycle: Molecular connections between aging and the circadian clock. *Ann. Med.* **2010**, *42*, 404–415.
189. Pattingre, S.; Tassa, A.; Qu, X.; Garuti, R.; Liang, X.H.; Mizushima, N.; Packer, M.; Schneider, M.D.; Levine, B. Bcl-2 antiapoptotic proteins inhibit Beclin 1-dependent autophagy. *Cell* **2005**, *122*, 927–939.
190. Wei, Y.; Pattingre, S.; Sinha, S.; Bassik, M.; Levine, B. JNK1-mediated phosphorylation of Bcl-2 regulates starvation-induced autophagy. *Mol. Cell.* **2008**, *30*, 678–688.
191. Nopparat, C.; Porter, J.E.; Ebadi, M.; Govitrapong, P. The mechanism for the neuroprotective effect of melatonin against methamphetamine-induced autophagy. *J. Pineal Res.* **2010**, *49*, 382–389.
192. Jeong, J.K.; Moon, M.H.; Lee, Y.J.; Seol, J.W.; Park, S.Y. Melatonin-induced autophagy protects against human prion protein-mediated neurotoxicity. *J. Pineal Res.* **2012**, *53*, 138–146.
193. Chang, C.F.; Huang, H.J.; Lee, H.C.; Hung, K.C.; Wu, R.T.; Lin, A.M. Melatonin attenuates kainic acid-induced neurotoxicity in mouse hippocampus via inhibition of autophagy and α -synuclein aggregation. *J. Pineal Res.* **2012**, *52*, 312–321.
194. Weinert, D. Age-dependent changes of the circadian system. *Chronobiol. Int.* **2000**, *17*, 261–283.
195. Reppert, S.M.; Weaver, D.R. Coordination of circadian timing in mammals. *Nature* **2002**, *418*, 935–941.
196. Vitaterna, M.H.; King, D.P.; Chang, A.M.; Kornhauser, J.M.; Lowrey, P.L.; McDonald, J.D.; Dove, W.F.; Pinto, L.H.; Turek, F.W.; Takahashi, J.S. Mutagenesis and mapping of a mouse gene, *Clock*, essential for circadian behavior. *Science* **1994**, *264*, 719–725.
197. Asher, G.; Schibler, U. A CLOCK-less clock. *Trends Cell Biol.* **2006**, *16*, 547–549.
198. Debruyne, J.P.; Noton, E.; Lambert, C.M.; Maywood, E.S.; Weaver, D.R.; Reppert, S.M. A clock shock: Mouse CLOCK is not required for circadian oscillator function. *Neuron* **2006**, *50*, 465–477.
199. Froy, O.; Chang, D.C.; Reppert, S.M. Redox potential: Differential roles in dCRY and mCRY1 functions. *Curr. Biol.* **2002**, *12*, 147–152.
200. Dunlap, J.C. Molecular bases for circadian clocks. *Cell* **1999**, *96*, 271–290.
201. Preitner, N.; Damiola, F.; Lopez-Molina, L.; Zakany, J.; Duboule, D.; Albrecht, U.; Schibler, U. The orphan nuclear receptor REV-ERB α controls circadian transcription within the positive limb of the mammalian circadian oscillator. *Cell* **2002**, *110*, 251–260.
202. Sato, T.K.; Panda, S.; Miraglia, L.J.; Reyes, T.M.; Rudic, R.D.; McNamara, P.; Naik, K.A.; FitzGerald, G.A.; Kay, S.A.; Hogenesch, J.B. A functional genomics strategy reveals Rora as a component of the mammalian circadian clock. *Neuron* **2004**, *43*, 527–537.
203. Ueda, H.R.; Hayashi, S.; Chen, W.; Sano, M.; Machida, M.; Shigeyoshi, Y.; Iino, M.; Hashimoto, S. System-level identification of transcriptional circuits underlying mammalian circadian clocks. *Nat. Genet.* **2005**, *37*, 187–192.

204. Harms, E.; Kivimae, S.; Young, M.W.; Saez, L. Posttranscriptional and posttranslational regulation of clock genes. *J. Biol. Rhythm.* **2004**, *19*, 361–373.
205. Jasser, S.A.; Blask, D.E.; Brainard, G.C. Light during darkness and cancer: Relationships in circadian photoreception and tumor biology. *Cancer Causes Control* **2006**, *17*, 515–523.
206. Van Gelder, R.N. Non-visual photoreception: Sensing light without sight. *Curr. Biol.* **2008**, *18*, R38–R39.
207. Pevet, P.; Challet, E. Melatonin: Both master clock output and internal time-giver in the circadian clocks network. *J. Physiol. Paris* **2011**, *105*, 170–182.
208. Schroeder, A.M.; Colwell, C.S. How to fix a broken clock. *Trends Pharmacol. Sci.* **2013**, *34*, 605–619.
209. Torres-Farfan, C.; Seron-Ferre, M.; Dinet, V.; Korf, H.W. Immunocytochemical demonstration of day/night changes of clock gene protein levels in the murine adrenal gland: Differences between melatonin-proficient (C3H) and melatonin-deficient (C57BL) mice. *J. Pineal Res.* **2006**, *40*, 64–70.
210. Uz, T.; Akhisaroglu, M.; Ahmed, R.; Manev, H. The pineal gland is critical for circadian Period1 expression in the striatum and for circadian cocaine sensitization in mice. *Neuropsychopharmacology* **2003**, *28*, 2117–2123.
211. Imbesi, M.; Arslan, A.D.; Yildiz, S.; Sharma, R.; Gavin, D.; Tun, N.; Manev, H.; Uz, T. The melatonin receptor MT1 is required for the differential regulatory actions of melatonin on neuronal “clock” gene expression in striatal neurons *in vitro*. *J. Pineal Res.* **2009**, *46*, 87–94.
212. Zeman, M.; Szantoova, K.; Stebelova, K.; Mravec, B.; Herichova, I. Effect of rhythmic melatonin administration on clock gene expression in the suprachiasmatic nucleus and the heart of hypertensive TGR(mRen2)27 rats. *J. Hypertens. Suppl.* **2009**, *27*, S21–S26.
213. Crosio, C.; Cermakian, N.; Allis, C.D.; Sassone-Corsi, P. Light induces chromatin modification in cells of the mammalian circadian clock. *Nat. Neurosci.* **2000**, *3*, 1241–1247.
214. Etchegaray, J.P.; Lee, C.; Wade, P.A.; Reppert, S.M. Rhythmic histone acetylation underlies transcription in the mammalian circadian clock. *Nature* **2003**, *421*, 177–182.
215. Masri, S.; Sassone-Corsi, P. Plasticity and specificity of the circadian epigenome. *Nat. Neurosci.* **2010**, *13*, 1324–1329.
216. Ripperger, J.A.; Schibler, U. Rhythmic CLOCK-BMAL1 binding to multiple E-box motifs drives circadian Dbp transcription and chromatin transitions. *Nat. Genet.* **2006**, *38*, 369–374.
217. Welberg, L. Circadian rhythms: Methylation mediates clock plasticity. *Nat. Rev. Neurosci.* **2014**, *15*, doi:10.1038/nrn3712.
218. Azzi, A.; Dallmann, R.; Casserly, A.; Rehrauer, H.; Patrignani, A.; Maier, B.; Kramer, A.; Brown, S.A. Circadian behavior is light-reprogrammed by plastic DNA methylation. *Nat. Neurosci.* **2014**, *17*, 377–382.
219. Katada, S.; Sassone-Corsi, P. The histone methyltransferase MLL1 permits the oscillation of circadian gene expression. *Nat. Struct. Mol. Biol.* **2010**, *17*, 1414–1421.
220. Doi, M.; Hirayama, J.; Sassone-Corsi, P. Circadian regulator CLOCK is a histone acetyltransferase. *Cell* **2006**, *125*, 497–508.

221. Hirayama, J.; Sahar, S.; Grimaldi, B.; Tamaru, T.; Takamatsu, K.; Nakahata, Y.; Sassone-Corsi, P. CLOCK-mediated acetylation of BMAL1 controls circadian function. *Nature* **2007**, *450*, 1086–1090.
222. Hochberg, I.; Hochberg, Z. Expanding the definition of hypothalamic obesity. *Obes. Rev.* **2010**, *11*, 709–721.
223. Herichova, I. Changes of physiological functions induced by shift work. *Endocr. Regul.* **2013**, *47*, 159–170.
224. Sookoian, S.; Pirola, C.J. Epigenetics of insulin resistance: An emerging field in translational medicine. *Curr. Diab. Rep.* **2013**, *13*, 229–237.
225. Nakabayashi, H.; Ohta, Y.; Yamamoto, M.; Susuki, Y.; Taguchi, A.; Tanabe, K.; Kondo, M.; Hatanaka, M.; Nagao, Y.; Tanizawa, Y. Clock-controlled output gene *Dbp* is a regulator of *Arnt/Hif-1 β* gene expression in pancreatic islet β -cells. *Biochem. Biophys. Res. Commun.* **2013**, *434*, 370–375.
226. Sahar, S.; Sassone-Corsi, P. Circadian rhythms and memory formation: Regulation by chromatin remodeling. *Front. Mol. Neurosci.* **2012**, *5*, doi:10.3389/fnmol.2012.00037.
227. Bishop, N.A.; Guarente, L. Genetic links between diet and lifespan: Shared mechanisms from yeast to humans. *Nat. Rev. Genet.* **2007**, *8*, 835–844.
228. Asher, G.; Gatfield, D.; Stratmann, M.; Reinke, H.; Dibner, C.; Kreppel, F.; Mostoslavsky, R.; Alt, F.W.; Schibler, U. SIRT1 regulates circadian clock gene expression through PER2 deacetylation. *Cell* **2008**, *134*, 317–328.
229. Grimaldi, B.; Nakahata, Y.; Kaluzova, M.; Masubuchi, S.; Sassone-Corsi, P. Chromatin remodeling, metabolism and circadian clocks: The interplay of CLOCK and SIRT1. *Int. J. Biochem. Cell Biol.* **2009**, *41*, 81–86.
230. Nakahata, Y.; Sahar, S.; Astarita, G.; Kaluzova, M.; Sassone-Corsi, P. Circadian control of the NAD⁺ salvage pathway by CLOCK-SIRT1. *Science* **2009**, *324*, 654–657.
231. Nakahata, Y.; Kaluzova, M.; Grimaldi, B.; Sahar, S.; Hirayama, J.; Chen, D.; Guarente, L.P.; Sassone-Corsi, P. The NAD⁺-dependent deacetylase SIRT1 modulates CLOCK-mediated chromatin remodeling and circadian control. *Cell* **2008**, *134*, 329–340.
232. Ramsey, K.M.; Yoshino, J.; Brace, C.S.; Abrassart, D.; Kobayashi, Y.; Marcheva, B.; Hong, H.K.; Chong, J.L.; Buhr, E.D.; Lee, C.; *et al.* Circadian clock feedback cycle through NAMPT-mediated NAD⁺ biosynthesis. *Science* **2009**, *324*, 651–654.
233. Garaulet, M.; Esteban Tardido, A.; Lee, Y.C.; Smith, C.E.; Parnell, L.D.; Ordovas, J.M. SIRT1 and CLOCK 3111T>C combined genotype is associated with evening preference and weight loss resistance in a behavioral therapy treatment for obesity. *Int. J. Obes.* **2012**, *36*, 1436–1441.
234. Kondratov, R.V.; Kondratova, A.A.; Gorbacheva, V.Y.; Vykhovanets, O.V.; Antoch, M.P. Early aging and age-related pathologies in mice deficient in BMAL1, the core component of the circadian clock. *Genes Dev.* **2006**, *20*, 1868–1873.
235. Dubrovsky, Y.V.; Samsa, W.E.; Kondratov, R.V. Deficiency of circadian protein CLOCK reduces lifespan and increases age-related cataract development in mice. *Aging* **2010**, *2*, 936–944.
236. Antoch, M.P.; Gorbacheva, V.Y.; Vykhovanets, O.; Toshkov, I.A.; Kondratov, R.V.; Kondratova, A.A.; Lee, C.; Nikitin, A.Y. Disruption of the circadian clock due to the Clock mutation has discrete effects on aging and carcinogenesis. *Cell Cycle* **2008**, *7*, 1197–1204.

237. Fu, L.; Pelicano, H.; Liu, J.; Huang, P.; Lee, C. The circadian gene *Period2* plays an important role in tumor suppression and DNA damage response *in vivo*. *Cell* **2002**, *111*, 41–50.
238. Kondratova, A.A.; Kondratov, R.V. The circadian clock and pathology of the ageing brain. *Nat. Rev. Neurosci.* **2012**, *13*, 325–335.
239. Nakamura, T.J.; Nakamura, W.; Yamazaki, S.; Kudo, T.; Cutler, T.; Colwell, C.S.; Block, G.D. Age-related decline in circadian output. *J. Neurosci.* **2011**, *31*, 10201–10205.
240. Weinert, D. Circadian temperature variation and ageing. *Ageing Res. Rev.* **2010**, *9*, 51–60.
241. Jagota, A.; Kalyani, D. Effect of melatonin on age induced changes in daily serotonin rhythms in suprachiasmatic nucleus of male Wistar rat. *Biogerontology* **2010**, *11*, 299–308.
242. Palomba, M.; Nygard, M.; Florenzano, F.; Bertini, G.; Kristensson, K.; Bentivoglio, M. Decline of the presynaptic network, including GABAergic terminals, in the aging suprachiasmatic nucleus of the mouse. *J. Biol. Rhythm.* **2008**, *23*, 220–231.
243. Manikonda, P.K.; Jagota, A. Melatonin administration differentially affects age-induced alterations in daily rhythms of lipid peroxidation and antioxidant enzymes in male rat liver. *Biogerontology* **2012**, *13*, 511–524.
244. von Gall, C.; Weaver, D.R. Loss of responsiveness to melatonin in the aging mouse suprachiasmatic nucleus. *Neurobiol. Aging* **2008**, *29*, 464–470.
245. Karasek, M. Melatonin, human aging, and age-related diseases. *Exp. Gerontol.* **2004**, *39*, 1723–1729.
246. Poeggeler, B. Melatonin, aging, and age-related diseases: Perspectives for prevention, intervention, and therapy. *Endocrine* **2005**, *27*, 201–212.
247. Wu, Y.H.; Swaab, D.F. The human pineal gland and melatonin in aging and Alzheimer's disease. *J. Pineal Res.* **2005**, *38*, 145–152.
248. Anisimov, V.N.; Vinogradova, I.A.; Panchenko, A.V.; Popovich, I.G.; Zabezhinski, M.A. Light-at-night-induced circadian disruption, cancer and aging. *Curr. Aging Sci.* **2012**, *5*, 170–177.
249. Vinogradova, I.A.; Anisimov, V.N.; Bukalev, A.V.; Semenchenko, A.V.; Zabezhinski, M.A. Circadian disruption induced by light-at-night accelerates aging and promotes tumorigenesis in rats. *Aging* **2009**, *1*, 855–865.
250. Kondratov, R.V.; Vykhovanets, O.; Kondratova, A.A.; Antoch, M.P. Antioxidant *N*-acetyl-L-cysteine ameliorates symptoms of premature aging associated with the deficiency of the circadian protein BMAL1. *Aging* **2009**, *1*, 979–987.
251. Mattam, U.; Jagota, A. Differential role of melatonin in restoration of age-induced alterations in daily rhythms of expression of various clock genes in suprachiasmatic nucleus of male Wistar rats. *Biogerontology* **2014**, *15*, 257–268.
252. Pfeifer, U. Inverted diurnal rhythm of cellular autophagy in liver cells of rats fed a single daily meal. *Virchows Arch. B Cell Pathol.* **1972**, *10*, 1–3.
253. Pfeifer, U. Cellular autophagy and cell atrophy in the rat liver during long-term starvation. A quantitative morphological study with regard to diurnal variations. *Virchows Arch. B Cell Pathol.* **1973**, *12*, 195–211.
254. Pfeifer, U.; Scheller, H. A morphometric study of cellular autophagy including diurnal variations in kidney tubules of normal rats. *J. Cell Biol.* **1975**, *64*, 608–621.
255. Reme, C.E.; Sulser, M. Diurnal variation of autophagy in rod visual cells in the rat. *Albrecht Von Graefes Arch. Klin. Exp. Ophthalmol.* **1977**, *203*, 261–270.

256. Pfeifer, U.; Scheller, H.; Ormanns, W. Diurnal rhythm of lysosomal organelle decomposition in liver, kidney and pancreas. *Acta. Histochem. Suppl.* **1976**, *16*, 205–210.
257. Reme, C.; Wirz-Justice, A.; Rhyner, A.; Hofmann, S. Circadian rhythm in the light response of rat retinal disk-shedding and autophagy. *Brain Res.* **1986**, *369*, 356–360.
258. Pfeifer, U.; Bertling, J. A morphometric study of the inhibition of autophagic degradation during restorative growth of liver cells in rats re-fed after starvation. *Virchows Arch. B Cell Pathol.* **1977**, *24*, 109–120.
259. Sachdeva, U.M.; Thompson, C.B. Diurnal rhythms of autophagy: Implications for cell biology and human disease. *Autophagy* **2008**, *4*, 581–589.
260. Ma, D.; Lin, J.D. Circadian regulation of autophagy rhythm through transcription factor C/EBP β . *Autophagy* **2012**, *8*, 124–125.
261. Ma, D.; Li, S.; Molusky, M.M.; Lin, J.D. Circadian autophagy rhythm: A link between clock and metabolism? *Trends Endocrinol. MeTab.* **2012**, *23*, 319–325.
262. Cao, R.; Anderson, F.E.; Jung, Y.J.; Dziema, H.; Obrietan, K. Circadian regulation of mammalian target of rapamycin signaling in the mouse suprachiasmatic nucleus. *Neuroscience* **2011**, *181*, 79–88.
263. Zheng, X.; Sehgal, A. AKT and TOR signaling set the pace of the circadian pacemaker. *Curr. Biol.* **2010**, *20*, 1203–1208.
264. Cao, R.; Li, A.; Cho, H.Y.; Lee, B.; Obrietan, K. Mammalian target of rapamycin signaling modulates photic entrainment of the suprachiasmatic circadian clock. *J. Neurosci.* **2010**, *30*, 6302–6314.
265. Khapre, R.V.; Kondratova, A.A.; Patel, S.; Dubrovsky, Y.; Wrobel, M.; Antoch, M.P.; Kondratov, R.V. BMAL1-dependent regulation of the mTOR signaling pathway delays aging. *Aging* **2014**, *6*, 48–57.
266. Gerstner, J.R.; Yin, J.C. Circadian rhythms and memory formation. *Nat. Rev. Neurosci.* **2010**, *11*, 577–588.
267. Wang, L.M.; Dragich, J.M.; Kudo, T.; Odom, I.H.; Welsh, D.K.; O'Dell, T.J.; Colwell, C.S. Expression of the circadian clock gene *Period2* in the hippocampus: Possible implications for synaptic plasticity and learned behaviour. *ASN Neuro* **2009**, *1*, doi:10.1042/AN20090020.
268. Chaudhury, D.; Wang, L.M.; Colwell, C.S. Circadian regulation of hippocampal long-term potentiation. *J. Biol. Rhythms.* **2005**, *20*, 225–236.
269. Eckel-Mahan, K.L.; Phan, T.; Han, S.; Wang, H.; Chan, G.C.; Scheiner, Z.S.; Storm, D.R. Circadian oscillation of hippocampal MAPK activity and cAMP: Implications for memory persistence. *Nat. Neurosci.* **2008**, *11*, 1074–1082.
270. Bass, J.; Takahashi, J.S. Circadian integration of metabolism and energetics. *Science* **2010**, *330*, 1349–1354.
271. Gery, S.; Koefler, H.P. Circadian rhythms and cancer. *Cell Cycle* **2010**, *9*, 1097–1103.
272. Kyriacou, C.P.; Hastings, M.H. Circadian clocks: Genes, sleep, and cognition. *Trends Cogn. Sci.* **2010**, *14*, 259–267.
273. Young, M.E. The circadian clock within the heart: Potential influence on myocardial gene expression, metabolism, and function. *Am. J. Physiol. Heart Circ. Physiol.* **2006**, *290*, H1–H16.

274. Dardente, H.; Cermakian, N. Molecular circadian rhythms in central and peripheral clocks in mammals. *Chronobiol. Int.* **2007**, *24*, 195–213.
275. Gan, L.; Mucke, L. Paths of convergence: Sirtuins in aging and neurodegeneration. *Neuron* **2008**, *58*, 10–14.
276. Donmez, G.; Wang, D.; Cohen, D.E.; Guarente, L. SIRT1 suppresses β -amyloid production by activating the α -secretase gene ADAM10. *Cell* **2010**, *142*, 320–332.
277. Min, S.W.; Cho, S.H.; Zhou, Y.; Schroeder, S.; Haroutunian, V.; Seeley, W.W.; Huang, E.J.; Shen, Y.; Masliah, E.; Mukherjee, C.; *et al.* Acetylation of tau inhibits its degradation and contributes to tauopathy. *Neuron* **2010**, *67*, 953–966.
278. Kim, D.; Nguyen, M.D.; Dobbin, M.M.; Fischer, A.; Sananbenesi, F.; Rodgers, J.T.; Delalle, I.; Baur, J.A.; Sui, G.; Armour, S.M.; *et al.* SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer’s disease and amyotrophic lateral sclerosis. *EMBO J.* **2007**, *26*, 3169–3179.
279. Gao, J.; Wang, W.Y.; Mao, Y.W.; Graff, J.; Guan, J.S.; Pan, L.; Mak, G.; Kim, D.; Su, S.C.; Tsai, L.H. A novel pathway regulates memory and plasticity via SIRT1 and miR-134. *Nature* **2010**, *466*, 1105–1109.
280. Michan, S.; Li, Y.; Chou, M.M.; Parrella, E.; Ge, H.; Long, J.M.; Allard, J.S.; Lewis, K.; Miller, M.; Xu, W.; *et al.* SIRT1 is essential for normal cognitive function and synaptic plasticity. *J. Neurosci.* **2010**, *30*, 9695–9707.

© 2014 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (<http://creativecommons.org/licenses/by/4.0/>).